Field medical engagements, stakeholder profiles, coverage and exchange quality. Records sync from Veeva CRM; manual records are entered here.
Unique stakeholders engaged
Safety-flagged
Submitted and reviewed engagements, FY2026
Totals: Jan 32 · Feb 24 · Mar 30 · Apr 32 · May 31 · Jun 28 · Jul 22 · Aug 26 · Sep 13
| Date | Stakeholder | MSL | Type | Format | Product | Topics | Insights | Flags | Status | Source | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 Sept 2026 | Dr. Emiko Vogel Tier 3 Charité Berlin | JWJames Whitfield | Scientific exchange | In person | Vantrexa | Duration of responseComparator checkpoint monotherapy+1 | 0 | — | Reviewed | Veeva CRM | ENG-0048 |
| 15 Sept 2026 | Dr. Chloé Fischer Tier 3 Kyoto University Hospital | JWJames Whitfield | Scientific exchange | Virtual | Vantrexa | Elderly / ECOG 2 patientsComparator checkpoint monotherapy+1 | 0 | — | Draft | Veeva CRM | ENG-0093 |
| 14 Sept 2026 | Dr. Chloé Dubois Tier 3 UCLH | RARachel Adeyemi | Scientific exchange | Virtual | Vantrexa | Infusion-reaction management | 1 | MI request | Submitted | Veeva CRM | ENG-0002 |
| 13 Sept 2026 | Dr. Tomoko Ueda Tier 2 Osaka University Hospital | MTMei Tanaka | Scientific exchange | In person | Vantrexa | PD-L1 testing turnaround | 1 | — | Submitted | Manual | ENG-0003 |
| 12 Sept 2026 | Dr. Noor Nakamura Tier 2 Hospital La Paz | RARachel Adeyemi | Congress meeting | Phone | Vantrexa | Infusion-reaction management | 0 | — | Submitted | Veeva CRM | ENG-0052 |
| 12 Sept 2026 | Dr. Zoë Vogel Tier 2 IEO Milano | LOLuis Ortega | Congress meeting | Phone | Lumeva | Medication-overuse headacheSwitching between CGRP agents | 0 | MI request | Draft | Manual | ENG-0207 |
| 11 Sept 2026 | Prof. Benedikt Fischer Tier 1 Charité Berlin | ABDr. Anna Becker | Investigator meeting | In person | Nephrada | Steroid-sparing strategiesAPRIL pathway mechanism | 1 | Safety | Reviewed | Manual | ENG-0011 |
| 11 Sept 2026 | Dr. Ulrich Hayashi Tier 2 Christie NHS Foundation Trust | ABDr. Anna Becker | Medical education | Virtual | Nephrada | Patient-reported outcomesAPRIL pathway mechanism+1 | 0 | — | Reviewed | Veeva CRM | ENG-0148 |
| 10 Sept 2026 | Dr. Andrea Abbott Tier 1 Memorial Sloan Kettering | JWJames Whitfield | Scientific exchange | In person | Vantrexa | Brain-metastasis subgroup dataChemotherapy-free first line | 1 | — | Reviewed | Veeva CRM | ENG-0007 |
| 08 Sept 2026 | Dr. Ingrid Bauer Tier 1 Hospital Clínic Barcelona | LOLuis Ortega | Medical education | In person | Lumeva | Medication-overuse headacheChronic migraine data | 0 | MI request | Reviewed | Veeva CRM | ENG-0180 |
| 07 Sept 2026 | Dr. Mariana Rossi Tier 3 Royal Marsden | JWJames Whitfield | Payer / HTA meeting | In person | Vantrexa | Elderly / ECOG 2 patientsComparator checkpoint monotherapy+1 | 0 | — | Reviewed | Veeva CRM | ENG-0050 |
| 07 Sept 2026 | Dr. Gabriel Rossi Tier 1 Guy's and St Thomas' | ABDr. Anna Becker | Congress meeting | In person | Nephrada | Treatment burden and fatigue | 1 | — | Reviewed | Veeva CRM | ENG-0156 |
| 06 Sept 2026 | Dr. Chloé Xu Tier 2 Gustave Roussy | MTMei Tanaka | Investigator meeting | In person | Vantrexa | Brain-metastasis subgroup dataSequencing after progression+1 | 0 | — | Reviewed | Veeva CRM | ENG-0100 |
| 03 Sept 2026 | Dr. Rosa Garcia Tier 3 Kyoto University Hospital | JWJames Whitfield | Payer / HTA meeting | In person | Lumeva | Dosing in hepatic impairmentReal-world persistence+1 | 0 | — | Reviewed | Veeva CRM | ENG-0210 |
| 02 Sept 2026 | Dr. Ximena Rossi Tier 1 Osaka University Hospital | MTMei Tanaka | Scientific exchange | In person | Vantrexa | Infusion-reaction managementDuration of response+1 | 1 | — | Reviewed | Veeva CRM | ENG-0092 |
| 31 Aug 2026 | Dr. Benedikt Lopez Tier 2 Mayo Clinic | RARachel Adeyemi | Scientific exchange | Phone | Aurelin | Adolescent populationPhase IIb efficacy | 0 | — | Reviewed | Manual | ENG-0235 |
| 29 Aug 2026 | Dr. Chloé Dubois Tier 3 Vall d'Hebron | RARachel Adeyemi | Medical education | In person | Vantrexa | Brain-metastasis subgroup dataChemotherapy-free first line | 0 | — | Reviewed | Manual | ENG-0004 |
| 29 Aug 2026 | Dr. Oscar Petit Tier 1 Ospedale San Raffaele | RARachel Adeyemi | Investigator meeting | Phone | Vantrexa | Duration of responseChemotherapy-free first line+1 | 0 | — | Reviewed | Veeva CRM | ENG-0030 |
| 29 Aug 2026 | Dr. Liam Quinn Tier 1 Royal Marsden | JWJames Whitfield | Investigator meeting | Virtual | Vantrexa | Sequencing after progressionComparator checkpoint monotherapy | 0 | MI request | Reviewed | Veeva CRM | ENG-0110 |
| 25 Aug 2026 | Dr. Chloé Xu Tier 2 Gustave Roussy | MTMei Tanaka | Scientific exchange | In person | Vantrexa | PD-L1 testing turnaroundSequencing after progression | 0 | — | Reviewed | Veeva CRM | ENG-0102 |
| 24 Aug 2026 | Dr. Javier Zimmermann Tier 2 Christie NHS Foundation Trust | ABDr. Anna Becker | Medical education | In person | Nephrada | APRIL pathway mechanismTreatment burden and fatigue+1 | 0 | — | Reviewed | Veeva CRM | ENG-0120 |
| 22 Aug 2026 | Dr. Zoë Bauer Tier 2 McGill University Health Centre | LOLuis Ortega | Scientific exchange | In person | Lumeva | Dosing in hepatic impairmentDrug interactions+1 | 1 | — | Reviewed | Manual | ENG-0187 |
| 21 Aug 2026 | Dr. Mariana Sato Tier 2 Uniklinik Köln | JWJames Whitfield | Scientific exchange | In person | Vantrexa | Duration of response | 0 | — | Reviewed | Veeva CRM | ENG-0065 |
| 18 Aug 2026 | Dr. Katarina Rossi Tier 3 Charité Berlin | JWJames Whitfield | Payer / HTA meeting | Virtual | Lumeva | Dosing in hepatic impairment | 1 | MI request | Reviewed | Veeva CRM | ENG-0172 |
| 17 Aug 2026 | Dr. Emiko Quinn Tier 3 Kyoto University Hospital | JWJames Whitfield | Scientific exchange | In person | Vantrexa | Sequencing after progression | 0 | — | Reviewed | Veeva CRM | ENG-0018 |
| 17 Aug 2026 | Dr. Hiroshi Weber Tier 2 Princess Margaret Cancer Centre | JWJames Whitfield | Scientific exchange | In person | Lumeva | Switching between CGRP agentsDosing in hepatic impairment+1 | 1 | — | Reviewed | Veeva CRM | ENG-0221 |
| 15 Aug 2026 | Dr. Ximena Eriksen Tier 3 Vall d'Hebron | MTMei Tanaka | Scientific exchange | In person | Vantrexa | Sequencing after progression | 0 | — | Reviewed | Veeva CRM | ENG-0033 |
| 14 Aug 2026 | Dr. William Jensen Tier 2 NICE technical team | ABDr. Anna Becker | Payer / HTA meeting | Virtual | Nephrada | eGFR slope interpretationProteinuria as surrogate endpoint | 1 | — | Reviewed | Manual | ENG-0066 |
| 14 Aug 2026 | Dr. Benedikt Lopez Tier 3 UCLH | JWJames Whitfield | Scientific exchange | Virtual | Vantrexa | PD-L1 testing turnaroundBrain-metastasis subgroup data+1 | 0 | — | Reviewed | Veeva CRM | ENG-0106 |
| 12 Aug 2026 | Dr. Oscar Petit Tier 1 Ospedale San Raffaele | RARachel Adeyemi | Scientific exchange | In person | Vantrexa | Sequencing after progression | 0 | — | Reviewed | Veeva CRM | ENG-0024 |
| 11 Aug 2026 | Dr. Liam Quinn Tier 1 Royal Marsden | JWJames Whitfield | Scientific exchange | Phone | Vantrexa | Brain-metastasis subgroup data | 1 | MI request | Reviewed | Veeva CRM | ENG-0096 |
| 10 Aug 2026 | Dr. Javier Ivanova Tier 1 Johns Hopkins | JWJames Whitfield | Scientific exchange | Virtual | Vantrexa | Chemotherapy-free first line | 1 | MI request | Reviewed | Manual | ENG-0068 |
| 10 Aug 2026 | Dr. Gabriel Kimura Tier 1 UCLH | RARachel Adeyemi | Advisory board | In person | Aurelin | JAK1/TYK2 selectivityLong-term safety monitoring+1 | 0 | — | Reviewed | Manual | ENG-0230 |
| 09 Aug 2026 | Dr. Chloé Dubois Tier 3 UCLH | JWJames Whitfield | Payer / HTA meeting | In person | Vantrexa | Sequencing after progressionDuration of response | 0 | MI request | Reviewed | Veeva CRM | ENG-0057 |
| 09 Aug 2026 | Dr. Chloé Xu Tier 2 Gustave Roussy | MTMei Tanaka | Congress meeting | In person | Vantrexa | PD-L1 testing turnaround | 1 | — | Reviewed | Veeva CRM | ENG-0112 |
| 08 Aug 2026 | Dr. Oscar Zimmermann Tier 2 UCSF Medical Center | RARachel Adeyemi | Investigator meeting | Virtual | Vantrexa | Brain-metastasis subgroup data | 1 | MI request | Reviewed | Veeva CRM | ENG-0090 |
| 07 Aug 2026 | Dr. Rosa Kimura Tier 2 Christie NHS Foundation Trust | MTMei Tanaka | Scientific exchange | Phone | Vantrexa | Comparator checkpoint monotherapyElderly / ECOG 2 patients+1 | 0 | — | Reviewed | Veeva CRM | ENG-0099 |
| 05 Aug 2026 | Dr. Emiko Quinn Tier 2 A.C. Camargo Cancer Center | LOLuis Ortega | Congress meeting | Phone | Lumeva | Chronic migraine dataSwitching between CGRP agents | 0 | — | Reviewed | Manual | ENG-0226 |
| 03 Aug 2026 | Dr. Farah Garcia Tier 3 Hôpital Pitié-Salpêtrière | JWJames Whitfield | Advisory board | In person | Vantrexa | Sequencing after progressionComparator checkpoint monotherapy | 0 | — | Reviewed | Manual | ENG-0043 |
| 03 Aug 2026 | Dr. Ulrich Hayashi Tier 2 Christie NHS Foundation Trust | ABDr. Anna Becker | Congress meeting | Virtual | Nephrada | APRIL pathway mechanism | 0 | — | Reviewed | Veeva CRM | ENG-0162 |
| 01 Aug 2026 | Dr. Yuki Meyer Tier 1 Guy's and St Thomas' | ABDr. Anna Becker | Scientific exchange | In person | Nephrada | eGFR slope interpretation | 1 | — | Reviewed | Veeva CRM | ENG-0124 |
| 31 Jul 2026 | Dr. Benedikt Xu Tier 2 Universitätsklinikum Heidelberg | ABDr. Anna Becker | Scientific exchange | Phone | Nephrada | Proteinuria as surrogate endpointAPRIL pathway mechanism | 0 | — | Reviewed | Veeva CRM | ENG-0157 |
| 30 Jul 2026 | Dr. Gabriel Ueda Tier 1 Institut Curie | RARachel Adeyemi | Medical education | Phone | Vantrexa | PD-L1 testing turnaround | 0 | — | Reviewed | Veeva CRM | ENG-0097 |
| 28 Jul 2026 | Dr. Farah Kimura Tier 3 Memorial Sloan Kettering | JWJames Whitfield | Scientific exchange | Virtual | Vantrexa | Chemotherapy-free first line | 0 | — | Reviewed | Veeva CRM | ENG-0064 |
| 26 Jul 2026 | Dr. Ximena Jensen Tier 1 Hospital La Paz | LOLuis Ortega | Scientific exchange | Virtual | Lumeva | Drug interactionsMedication-overuse headache | 1 | MI request | Reviewed | Veeva CRM | ENG-0185 |
| 25 Jul 2026 | Dr. Benedikt Dubois Tier 2 LMU Klinikum München | RARachel Adeyemi | Investigator meeting | Virtual | Vantrexa | Elderly / ECOG 2 patientsPD-L1 testing turnaround | 0 | — | Reviewed | Veeva CRM | ENG-0073 |
| 24 Jul 2026 | Dr. Yuki Quinn Tier 2 Osaka University Hospital | RARachel Adeyemi | Scientific exchange | Virtual | Vantrexa | Brain-metastasis subgroup dataSequencing after progression | 0 | — | Reviewed | Veeva CRM | ENG-0053 |
| 24 Jul 2026 | Dr. Rosa Garcia Tier 3 Kyoto University Hospital | JWJames Whitfield | Scientific exchange | Virtual | Lumeva | Chronic migraine dataSwitching between CGRP agents+1 | 0 | MI request | Reviewed | Veeva CRM | ENG-0214 |
| 23 Jul 2026 | Dr. Noor Abbott Tier 2 Hospital Clínic Barcelona | RARachel Adeyemi | Payer / HTA meeting | Phone | Vantrexa | Comparator checkpoint monotherapy | 0 | — | Reviewed | Veeva CRM | ENG-0023 |
| 22 Jul 2026 | Dr. Gabriel Ueda Tier 2 National Cancer Center Tokyo | RARachel Adeyemi | Scientific exchange | In person | Vantrexa | Comparator checkpoint monotherapyPD-L1 testing turnaround | 0 | — | Reviewed | Veeva CRM | ENG-0029 |
| 22 Jul 2026 | Dr. Benedikt Castellano Tier 1 National Cancer Center Tokyo | LOLuis Ortega | Scientific exchange | Virtual | Lumeva | Drug interactions | 0 | — | Reviewed | Veeva CRM | ENG-0213 |
| 22 Jul 2026 | Dr. Paola Castellano Tier 1 Vall d'Hebron | LOLuis Ortega | Scientific exchange | In person | Lumeva | Medication-overuse headacheChronic migraine data | 1 | — | Reviewed | Veeva CRM | ENG-0044 |
| 21 Jul 2026 | Dr. Ingrid Bauer Tier 1 Hospital Clínic Barcelona | LOLuis Ortega | Scientific exchange | Phone | Lumeva | Chronic migraine dataMedication-overuse headache | 1 | — | Reviewed | Veeva CRM | ENG-0165 |
| 20 Jul 2026 | Dr. Benedikt Vogel Tier 1 Universitätsklinikum Heidelberg | ABDr. Anna Becker | Congress meeting | Virtual | Nephrada | APRIL pathway mechanismSteroid-sparing strategies | 0 | — | Reviewed | Veeva CRM | ENG-0134 |
| 18 Jul 2026 | Dr. Gabriel Yamamoto Tier 1 Christie NHS Foundation Trust | ABDr. Anna Becker | Congress meeting | Virtual | Nephrada | Steroid-sparing strategies | 0 | — | Reviewed | Veeva CRM | ENG-0149 |
| 17 Jul 2026 | Dr. Javier Zimmermann Tier 2 Christie NHS Foundation Trust | ABDr. Anna Becker | Scientific exchange | Virtual | Nephrada | Patient-reported outcomesAPRIL pathway mechanism+1 | 0 | — | Reviewed | Veeva CRM | ENG-0158 |
| 17 Jul 2026 | Dr. Farah Fischer Tier 2 MD Anderson Cancer Center | JWJames Whitfield | Scientific exchange | In person | Lumeva | Real-world persistenceDosing in hepatic impairment+1 | 0 | — | Reviewed | Veeva CRM | ENG-0181 |
| 11 Jul 2026 | Dr. Katarina Rossi Tier 3 Charité Berlin | JWJames Whitfield | Payer / HTA meeting | Phone | Lumeva | Chronic migraine dataDrug interactions+1 | 0 | — | Reviewed | Manual | ENG-0179 |
| 10 Jul 2026 | Dr. Noor Sato Tier 1 Royal Melbourne Hospital | LOLuis Ortega | Medical education | Virtual | Lumeva | Switching between CGRP agents | 1 | MI request | Reviewed | Veeva CRM | ENG-0204 |
| 07 Jul 2026 | Dr. Gabriel Yamamoto Tier 1 Christie NHS Foundation Trust | ABDr. Anna Becker | Payer / HTA meeting | In person | Nephrada | Steroid-sparing strategiesAPRIL pathway mechanism+1 | 1 | — | Reviewed | Veeva CRM | ENG-0138 |
| 06 Jul 2026 | Dr. Mariana Sato Tier 2 Uniklinik Köln | JWJames Whitfield | Scientific exchange | Phone | Vantrexa | PD-L1 testing turnaround | 1 | — | Reviewed | Veeva CRM | ENG-0104 |
| 04 Jul 2026 | Dr. Javier Ivanova Tier 1 Johns Hopkins | JWJames Whitfield | Advisory board | In person | Vantrexa | Elderly / ECOG 2 patientsBrain-metastasis subgroup data+1 | 0 | — | Reviewed | Veeva CRM | ENG-0116 |
| 04 Jul 2026 | Dr. Benedikt Dubois Tier 3 Memorial Sloan Kettering | LOLuis Ortega | Scientific exchange | In person | Lumeva | Real-world persistenceMedication-overuse headache | 1 | — | Reviewed | Veeva CRM | ENG-0190 |
| 30 Jun 2026 | Dr. William Ivanova Tier 1 Gustave Roussy | JWJames Whitfield | Scientific exchange | Virtual | Vantrexa | Comparator checkpoint monotherapy | 0 | — | Reviewed | Veeva CRM | ENG-0108 |
| 30 Jun 2026 | Dr. Noor Sato Tier 1 Royal Melbourne Hospital | LOLuis Ortega | Congress meeting | In person | Lumeva | Chronic migraine data | 1 | — | Reviewed | Veeva CRM | ENG-0188 |
| 28 Jun 2026 | Dr. Chloé Dubois Tier 3 Vall d'Hebron | RARachel Adeyemi | Advisory board | In person | Vantrexa | Comparator checkpoint monotherapySequencing after progression+1 | 0 | — | Reviewed | Veeva CRM | ENG-0089 |
| 28 Jun 2026 | Dr. Rosa Jensen Tier 3 Uniklinik Köln | ABDr. Anna Becker | Scientific exchange | Virtual | Nephrada | APRIL pathway mechanismeGFR slope interpretation | 0 | — | Reviewed | Manual | ENG-0147 |
| 27 Jun 2026 | Dr. Ingrid Petit Tier 3 LMU Klinikum München | JWJames Whitfield | Scientific exchange | In person | Lumeva | Medication-overuse headacheChronic migraine data | 0 | — | Reviewed | Veeva CRM | ENG-0182 |
| 26 Jun 2026 | Dr. Benedikt Xu Tier 2 Universitätsklinikum Heidelberg | ABDr. Anna Becker | Medical education | Phone | Nephrada | eGFR slope interpretationSteroid-sparing strategies | 0 | — | Reviewed | Veeva CRM | ENG-0152 |
| 24 Jun 2026 | Dr. Valentina Hayashi Tier 2 Hospital Clínic Barcelona | RARachel Adeyemi | Congress meeting | Virtual | Vantrexa | Chemotherapy-free first line | 1 | — | Reviewed | Veeva CRM | ENG-0017 |
| 24 Jun 2026 | Dr. Zoë Bauer Tier 2 McGill University Health Centre | LOLuis Ortega | Scientific exchange | Virtual | Lumeva | Chronic migraine dataReal-world persistence+1 | 1 | — | Reviewed | Manual | ENG-0167 |
| 22 Jun 2026 | Dr. Daniel Tanaka Tier 3 Policlinico Gemelli | JWJames Whitfield | Investigator meeting | Virtual | Vantrexa | Comparator checkpoint monotherapyInfusion-reaction management | 0 | — | Reviewed | Manual | ENG-0015 |
| 22 Jun 2026 | Dr. Sven Fischer Tier 3 Hôpital Pitié-Salpêtrière | RARachel Adeyemi | Congress meeting | In person | Vantrexa | PD-L1 testing turnaround | 0 | — | Reviewed | Manual | ENG-0078 |
| 22 Jun 2026 | Dr. Ulrich Hayashi Tier 2 Christie NHS Foundation Trust | ABDr. Anna Becker | Scientific exchange | Virtual | Nephrada | eGFR slope interpretationSteroid-sparing strategies+1 | 1 | — | Reviewed | Veeva CRM | ENG-0155 |
| 18 Jun 2026 | Dr. Liam Quinn Tier 1 Royal Marsden | RARachel Adeyemi | Scientific exchange | In person | Vantrexa | Sequencing after progression | 1 | — | Reviewed | Veeva CRM | ENG-0021 |
| 18 Jun 2026 | Dr. Benedikt Vogel Tier 1 Universitätsklinikum Heidelberg | ABDr. Anna Becker | Investigator meeting | In person | Nephrada | Patient-reported outcomesProteinuria as surrogate endpoint | 0 | — | Reviewed | Veeva CRM | ENG-0145 |
| 17 Jun 2026 | Dr. Rosa Garcia Tier 3 Kyoto University Hospital | JWJames Whitfield | Congress meeting | In person | Lumeva | Switching between CGRP agents | 0 | — | Reviewed | Veeva CRM | ENG-0197 |
| 15 Jun 2026 | Dr. Liam Quinn Tier 1 Royal Marsden | JWJames Whitfield | Scientific exchange | Phone | Vantrexa | Sequencing after progressionChemotherapy-free first line+1 | 0 | — | Reviewed | Veeva CRM | ENG-0072 |
| 13 Jun 2026 | Dr. Quentin Ueda Tier 1 Guy's and St Thomas' | ABDr. Anna Becker | Scientific exchange | Virtual | Nephrada | Treatment burden and fatigueProteinuria as surrogate endpoint+1 | 0 | — | Reviewed | Manual | ENG-0163 |
| 12 Jun 2026 | Dr. Sven Eriksen Tier 2 Universitätsklinikum Heidelberg | ABDr. Anna Becker | Medical education | In person | Nephrada | APRIL pathway mechanismSteroid-sparing strategies | 1 | — | Reviewed | Manual | ENG-0135 |
| 12 Jun 2026 | Dr. Yuki Castellano Tier 3 Gustave Roussy | ABDr. Anna Becker | Scientific exchange | In person | Nephrada | Patient-reported outcomesProteinuria as surrogate endpoint | 0 | — | Reviewed | Veeva CRM | ENG-0136 |
| 07 Jun 2026 | Dr. Emiko Quinn Tier 3 Kyoto University Hospital | JWJames Whitfield | Scientific exchange | In person | Vantrexa | PD-L1 testing turnaroundChemotherapy-free first line | 0 | — | Reviewed | Veeva CRM | ENG-0014 |
| 07 Jun 2026 | Dr. Oscar Xu Tier 3 IEO Milano | MTMei Tanaka | Scientific exchange | Phone | Vantrexa | Elderly / ECOG 2 patientsBrain-metastasis subgroup data | 0 | — | Reviewed | Veeva CRM | ENG-0027 |
| 07 Jun 2026 | Dr. Liam Quinn Tier 1 Royal Marsden | JWJames Whitfield | Medical education | Virtual | Vantrexa | Comparator checkpoint monotherapyDuration of response | 0 | — | Reviewed | Veeva CRM | ENG-0063 |
| 07 Jun 2026 | Dr. Rosa Zimmermann Tier 2 Peter MacCallum Cancer Centre | LOLuis Ortega | Scientific exchange | Virtual | Lumeva | Drug interactions | 0 | — | Reviewed | Veeva CRM | ENG-0218 |
| 06 Jun 2026 | Dr. William Jensen Tier 2 NICE technical team | RARachel Adeyemi | Investigator meeting | In person | Vantrexa | PD-L1 testing turnaround | 0 | — | Reviewed | Veeva CRM | ENG-0035 |
| 05 Jun 2026 | Dr. Sven Abbott Tier 2 Policlinico Gemelli | MTMei Tanaka | Scientific exchange | Virtual | Vantrexa | Infusion-reaction managementElderly / ECOG 2 patients | 1 | — | Reviewed | Veeva CRM | ENG-0086 |
| 04 Jun 2026 | Dr. Liam Dubois Tier 1 Peter MacCallum Cancer Centre | LOLuis Ortega | Investigator meeting | In person | Lumeva | Switching between CGRP agentsMedication-overuse headache | 0 | MI request | Reviewed | Veeva CRM | ENG-0202 |
| 01 Jun 2026 | Dr. Javier Kimura Tier 3 Gustave Roussy | ABDr. Anna Becker | Scientific exchange | In person | Nephrada | APRIL pathway mechanismeGFR slope interpretation+1 | 0 | — | Reviewed | Veeva CRM | ENG-0137 |
| 01 Jun 2026 | Dr. Benedikt Rossi Tier 3 Hospital Clínic Barcelona | LOLuis Ortega | Scientific exchange | In person | Lumeva | Drug interactions | 1 | — | Reviewed | Veeva CRM | ENG-0205 |
| 01 Jun 2026 | Dr. Quentin Zimmermann Tier 2 Universitätsklinikum Heidelberg | RARachel Adeyemi | Scientific exchange | In person | Aurelin | Phase IIb efficacyAdolescent population+1 | 0 | — | Reviewed | Veeva CRM | ENG-0239 |
| 31 May 2026 | Dr. Zoë Bauer Tier 2 McGill University Health Centre | LOLuis Ortega | Scientific exchange | Phone | Lumeva | Dosing in hepatic impairmentDrug interactions+1 | 0 | — | Reviewed | Veeva CRM | ENG-0168 |
| 30 May 2026 | Dr. Quentin Ueda Tier 2 LMU Klinikum München | RARachel Adeyemi | Scientific exchange | In person | Aurelin | Long-term safety monitoringAdolescent population+1 | 0 | — | Reviewed | Veeva CRM | ENG-0238 |
| 29 May 2026 | Dr. Rosa Kimura Tier 2 Christie NHS Foundation Trust | MTMei Tanaka | Congress meeting | In person | Vantrexa | PD-L1 testing turnaroundDuration of response+1 | 0 | — | Reviewed | Veeva CRM | ENG-0115 |
| 27 May 2026 | Dr. Benedikt Dubois Tier 2 LMU Klinikum München | RARachel Adeyemi | Medical education | Virtual | Vantrexa | Duration of response | 0 | — | Reviewed | Veeva CRM | ENG-0013 |
| 26 May 2026 | Dr. Gabriel Ueda Tier 1 Institut Curie | RARachel Adeyemi | Scientific exchange | Phone | Vantrexa | Elderly / ECOG 2 patients | 0 | — | Reviewed | Veeva CRM | ENG-0118 |
| 24 May 2026 | Dr. Oscar Yamamoto Tier 3 Memorial Sloan Kettering | JWJames Whitfield | Investigator meeting | In person | Vantrexa | Chemotherapy-free first line | 1 | — | Reviewed | Manual | ENG-0071 |
| 24 May 2026 | Dr. Ulrich Zimmermann Tier 2 Cleveland Clinic | MTMei Tanaka | Scientific exchange | In person | Vantrexa | Brain-metastasis subgroup dataDuration of response | 0 | — | Reviewed | Veeva CRM | ENG-0114 |
| 24 May 2026 | Dr. Hiroshi Weber Tier 2 Princess Margaret Cancer Centre | JWJames Whitfield | Scientific exchange | In person | Lumeva | Chronic migraine dataSwitching between CGRP agents+1 | 0 | — | Reviewed | Veeva CRM | ENG-0196 |
| 19 May 2026 | Dr. Chloé Kimura Tier 1 Hôpital Pitié-Salpêtrière | MTMei Tanaka | Payer / HTA meeting | Virtual | Vantrexa | Comparator checkpoint monotherapyChemotherapy-free first line | 0 | — | Reviewed | Veeva CRM | ENG-0059 |
| 19 May 2026 | Dr. William Abbott Tier 3 Universitätsklinikum Heidelberg | RARachel Adeyemi | Medical education | Virtual | Vantrexa | Chemotherapy-free first lineSequencing after progression+1 | 0 | — | Reviewed | Manual | ENG-0113 |
| 18 May 2026 | Dr. Ulrich Abbott Tier 1 Hôpital Pitié-Salpêtrière | JWJames Whitfield | Medical education | Phone | Vantrexa | PD-L1 testing turnaround | 0 | — | Reviewed | Veeva CRM | ENG-0038 |
| 16 May 2026 | Dr. Mariana Lopez Tier 1 Hospital Sírio-Libanês | JWJames Whitfield | Scientific exchange | In person | Lumeva | Real-world persistenceDrug interactions | 1 | — | Reviewed | Veeva CRM | ENG-0198 |
| 16 May 2026 | Dr. Ximena Jensen Tier 1 Hospital La Paz | LOLuis Ortega | Advisory board | Phone | Lumeva | Chronic migraine dataMedication-overuse headache+1 | 1 | — | Reviewed | Manual | ENG-0223 |
| 15 May 2026 | Dr. Benedikt Xu Tier 2 Universitätsklinikum Heidelberg | ABDr. Anna Becker | Payer / HTA meeting | Virtual | Nephrada | eGFR slope interpretationPatient-reported outcomes+1 | 0 | — | Reviewed | Manual | ENG-0127 |
| 14 May 2026 | Dr. William Abbott Tier 3 Universitätsklinikum Heidelberg | RARachel Adeyemi | Advisory board | Phone | Vantrexa | Comparator checkpoint monotherapyDuration of response+1 | 0 | — | Reviewed | Manual | ENG-0067 |
| 14 May 2026 | Dr. Andrea Weber Tier 1 McGill University Health Centre | JWJames Whitfield | Investigator meeting | In person | Lumeva | Real-world persistenceMedication-overuse headache+1 | 0 | MI request | Reviewed | Veeva CRM | ENG-0215 |
| 12 May 2026 | Dr. Tomoko Xu Tier 1 Universitätsklinikum Heidelberg | LOLuis Ortega | Advisory board | Virtual | Lumeva | Dosing in hepatic impairment | 0 | — | Reviewed | Manual | ENG-0178 |
| 11 May 2026 | Dr. Emiko Tanaka Tier 1 Uniklinik Köln | JWJames Whitfield | Scientific exchange | Virtual | Vantrexa | Elderly / ECOG 2 patientsBrain-metastasis subgroup data+1 | 0 | — | Reviewed | Veeva CRM | ENG-0005 |
| 11 May 2026 | Dr. Ximena Olsen Tier 2 IEO Milano | LOLuis Ortega | Scientific exchange | Virtual | Lumeva | Switching between CGRP agents | 1 | — | Reviewed | Manual | ENG-0191 |
| 10 May 2026 | Dr. Daniel Weber Tier 1 Johns Hopkins | JWJames Whitfield | Advisory board | In person | Vantrexa | Chemotherapy-free first lineInfusion-reaction management | 1 | — | Reviewed | Veeva CRM | ENG-0020 |
| 10 May 2026 | Dr. William Abbott Tier 3 Universitätsklinikum Heidelberg | RARachel Adeyemi | Scientific exchange | Virtual | Vantrexa | Brain-metastasis subgroup dataChemotherapy-free first line | 1 | — | Reviewed | Veeva CRM | ENG-0077 |
| 08 May 2026 | Dr. Noor Abbott Tier 2 Hospital Clínic Barcelona | RARachel Adeyemi | Scientific exchange | In person | Vantrexa | Infusion-reaction management | 0 | Safety | Reviewed | Veeva CRM | ENG-0039 |
| 08 May 2026 | Dr. Daniel Weber Tier 1 Johns Hopkins | JWJames Whitfield | Scientific exchange | In person | Vantrexa | Duration of responsePD-L1 testing turnaround | 1 | — | Reviewed | Manual | ENG-0041 |
| 08 May 2026 | Dr. Sven Fischer Tier 3 Hôpital Pitié-Salpêtrière | RARachel Adeyemi | Investigator meeting | In person | Vantrexa | Elderly / ECOG 2 patients | 1 | — | Reviewed | Veeva CRM | ENG-0103 |
| 08 May 2026 | Dr. Gabriel Rossi Tier 1 Guy's and St Thomas' | ABDr. Anna Becker | Advisory board | In person | Nephrada | Treatment burden and fatigueSteroid-sparing strategies | 1 | — | Reviewed | Veeva CRM | ENG-0146 |
| 06 May 2026 | Dr. Quentin Quinn Tier 1 Institut Curie | ABDr. Anna Becker | Investigator meeting | Virtual | Nephrada | Treatment burden and fatigueeGFR slope interpretation+1 | 0 | — | Reviewed | Manual | ENG-0132 |
| 04 May 2026 | Dr. Mariana Rossi Tier 3 Royal Marsden | JWJames Whitfield | Medical education | Phone | Vantrexa | Brain-metastasis subgroup dataSequencing after progression | 0 | — | Reviewed | Veeva CRM | ENG-0031 |
| 03 May 2026 | Dr. Emiko Quinn Tier 3 Kyoto University Hospital | JWJames Whitfield | Scientific exchange | Virtual | Vantrexa | Sequencing after progressionElderly / ECOG 2 patients+1 | 0 | MI request | Reviewed | Veeva CRM | ENG-0009 |
| 03 May 2026 | Dr. Oscar Zimmermann Tier 2 UCSF Medical Center | RARachel Adeyemi | Scientific exchange | Phone | Vantrexa | Sequencing after progressionElderly / ECOG 2 patients | 1 | — | Reviewed | Veeva CRM | ENG-0046 |
| 02 May 2026 | Dr. Zoë Castellano Tier 2 UCLH | ABDr. Anna Becker | Scientific exchange | Phone | Nephrada | Patient-reported outcomesTreatment burden and fatigue | 0 | — | Reviewed | Veeva CRM | ENG-0123 |
| 02 May 2026 | Dr. Tomoko Quinn Tier 1 Hospital Sírio-Libanês | LOLuis Ortega | Congress meeting | Virtual | Lumeva | Chronic migraine data | 1 | — | Reviewed | Veeva CRM | ENG-0209 |
| 30 Apr 2026 | Dr. Sven Fischer Tier 3 Hôpital Pitié-Salpêtrière | RARachel Adeyemi | Payer / HTA meeting | Virtual | Vantrexa | Elderly / ECOG 2 patientsBrain-metastasis subgroup data | 0 | — | Reviewed | Manual | ENG-0001 |
| 30 Apr 2026 | Dr. Valentina Hayashi Tier 2 Hospital Clínic Barcelona | RARachel Adeyemi | Scientific exchange | Phone | Vantrexa | Elderly / ECOG 2 patientsDuration of response | 1 | — | Reviewed | Manual | ENG-0036 |
| 30 Apr 2026 | Dr. Javier Weber Tier 3 Osaka University Hospital | JWJames Whitfield | Scientific exchange | Phone | Vantrexa | PD-L1 testing turnaroundElderly / ECOG 2 patients | 1 | — | Reviewed | Veeva CRM | ENG-0056 |
| 28 Apr 2026 | Dr. Sven Eriksen Tier 2 Universitätsklinikum Heidelberg | ABDr. Anna Becker | Investigator meeting | Virtual | Nephrada | Patient-reported outcomesTreatment burden and fatigue | 0 | — | Reviewed | Manual | ENG-0129 |
| 27 Apr 2026 | Dr. Daniel Vogel Tier 3 LMU Klinikum München | ABDr. Anna Becker | Medical education | Virtual | Nephrada | eGFR slope interpretationProteinuria as surrogate endpoint | 0 | — | Reviewed | Manual | ENG-0121 |
| 25 Apr 2026 | Dr. Benedikt Dubois Tier 3 Memorial Sloan Kettering | LOLuis Ortega | Scientific exchange | Phone | Lumeva | Drug interactionsSwitching between CGRP agents+1 | 0 | — | Reviewed | Veeva CRM | ENG-0176 |
| 25 Apr 2026 | Dr. Andrea Fischer Tier 2 Osaka University Hospital | LOLuis Ortega | Scientific exchange | Virtual | Lumeva | Real-world persistence | 0 | — | Reviewed | Veeva CRM | ENG-0189 |
| 25 Apr 2026 | Dr. Ingrid Petit Tier 3 LMU Klinikum München | JWJames Whitfield | Scientific exchange | Phone | Lumeva | Medication-overuse headacheReal-world persistence | 1 | — | Reviewed | Veeva CRM | ENG-0206 |
| 24 Apr 2026 | Dr. Quentin Abbott Tier 2 Hospital Clínic Barcelona | LOLuis Ortega | Investigator meeting | In person | Lumeva | Drug interactions | 0 | — | Reviewed | Veeva CRM | ENG-0222 |
| 23 Apr 2026 | Dr. Ulrich Abbott Tier 1 Hôpital Pitié-Salpêtrière | JWJames Whitfield | Medical education | In person | Vantrexa | Duration of response | 1 | MI request | Reviewed | Veeva CRM | ENG-0098 |
| 22 Apr 2026 | Dr. Benedikt Dubois Tier 2 LMU Klinikum München | RARachel Adeyemi | Medical education | Phone | Vantrexa | PD-L1 testing turnaroundElderly / ECOG 2 patients+1 | 0 | — | Reviewed | Veeva CRM | ENG-0034 |
| 20 Apr 2026 | Dr. Ximena Fischer Tier 2 LMU Klinikum München | RARachel Adeyemi | Advisory board | Phone | Aurelin | JAK1/TYK2 selectivityAdolescent population | 0 | — | Reviewed | Veeva CRM | ENG-0227 |
| 20 Apr 2026 | Dr. Rosa Eriksen Tier 1 Johns Hopkins | RARachel Adeyemi | Medical education | In person | Aurelin | Phase IIb efficacyJAK1/TYK2 selectivity+1 | 0 | MI request | Reviewed | Veeva CRM | ENG-0233 |
| 19 Apr 2026 | Dr. Hiroshi Hayashi Tier 1 LMU Klinikum München | MTMei Tanaka | Scientific exchange | Phone | Vantrexa | Sequencing after progression | 0 | — | Reviewed | Veeva CRM | ENG-0101 |
| 18 Apr 2026 | Dr. Chloé Ivanova Tier 1 Hospital Clínic Barcelona | LOLuis Ortega | Scientific exchange | Virtual | Lumeva | Drug interactionsDosing in hepatic impairment+1 | 1 | — | Reviewed | Veeva CRM | ENG-0177 |
| 18 Apr 2026 | Dr. Andrea Weber Tier 1 McGill University Health Centre | JWJames Whitfield | Scientific exchange | Phone | Lumeva | Real-world persistenceDrug interactions | 0 | Safety | Reviewed | Veeva CRM | ENG-0194 |
| 17 Apr 2026 | Dr. Benedikt Castellano Tier 1 National Cancer Center Tokyo | LOLuis Ortega | Scientific exchange | In person | Lumeva | Drug interactionsReal-world persistence | 1 | — | Reviewed | Veeva CRM | ENG-0212 |
| 16 Apr 2026 | Dr. Daniel Weber Tier 1 Royal Marsden | ABDr. Anna Becker | Scientific exchange | Phone | Nephrada | Patient-reported outcomesProteinuria as surrogate endpoint | 1 | — | Reviewed | Veeva CRM | ENG-0160 |
| 16 Apr 2026 | Dr. Benedikt Rossi Tier 3 Hospital Clínic Barcelona | LOLuis Ortega | Scientific exchange | Virtual | Lumeva | Chronic migraine dataDosing in hepatic impairment | 0 | — | Reviewed | Veeva CRM | ENG-0217 |
| 14 Apr 2026 | Dr. Mariana Sato Tier 2 Uniklinik Köln | JWJames Whitfield | Medical education | Phone | Vantrexa | Comparator checkpoint monotherapyInfusion-reaction management+1 | 0 | MI request | Reviewed | Veeva CRM | ENG-0045 |
| 14 Apr 2026 | Dr. Hiroshi Petit Tier 1 MD Anderson Cancer Center | ABDr. Anna Becker | Scientific exchange | Virtual | Nephrada | Patient-reported outcomesProteinuria as surrogate endpoint+1 | 1 | — | Reviewed | Veeva CRM | ENG-0142 |
| 13 Apr 2026 | Dr. Emiko Tanaka Tier 1 Uniklinik Köln | JWJames Whitfield | Scientific exchange | Phone | Vantrexa | Elderly / ECOG 2 patientsDuration of response+1 | 1 | — | Reviewed | Veeva CRM | ENG-0008 |
| 12 Apr 2026 | Dr. Noor Nakamura Tier 2 Hospital La Paz | RARachel Adeyemi | Advisory board | Phone | Vantrexa | Brain-metastasis subgroup data | 0 | — | Reviewed | Veeva CRM | ENG-0081 |
| 12 Apr 2026 | Dr. Benedikt Vogel Tier 1 Universitätsklinikum Heidelberg | ABDr. Anna Becker | Investigator meeting | Virtual | Nephrada | Treatment burden and fatigue | 1 | — | Reviewed | Veeva CRM | ENG-0126 |
| 12 Apr 2026 | Dr. Paola Jensen Tier 2 LMU Klinikum München | ABDr. Anna Becker | Investigator meeting | In person | Nephrada | eGFR slope interpretation | 0 | — | Reviewed | Veeva CRM | ENG-0128 |
| 12 Apr 2026 | Dr. Noor Sato Tier 1 Royal Melbourne Hospital | LOLuis Ortega | Scientific exchange | In person | Lumeva | Medication-overuse headache | 0 | — | Reviewed | Veeva CRM | ENG-0219 |
| 11 Apr 2026 | Dr. Benedikt Ivanova Tier 2 Osaka University Hospital | RARachel Adeyemi | Scientific exchange | Phone | Vantrexa | Duration of responseInfusion-reaction management | 1 | — | Reviewed | Veeva CRM | ENG-0105 |
| 10 Apr 2026 | Dr. Liam Quinn Tier 3 Institut Curie | ABDr. Anna Becker | Advisory board | In person | Nephrada | Treatment burden and fatigueeGFR slope interpretation+1 | 0 | — | Reviewed | Veeva CRM | ENG-0164 |
| 09 Apr 2026 | Dr. Benedikt Fischer Tier 2 Guy's and St Thomas' | JWJames Whitfield | Scientific exchange | In person | Vantrexa | PD-L1 testing turnaround | 0 | — | Reviewed | Manual | ENG-0117 |
| 06 Apr 2026 | Dr. Javier Petit Tier 2 MD Anderson Cancer Center | RARachel Adeyemi | Medical education | In person | Aurelin | Adolescent populationLong-term safety monitoring | 0 | — | Reviewed | Veeva CRM | ENG-0237 |
| 01 Apr 2026 | Dr. Emiko Vogel Tier 3 Charité Berlin | JWJames Whitfield | Scientific exchange | Virtual | Vantrexa | Elderly / ECOG 2 patients | 1 | — | Reviewed | Veeva CRM | ENG-0088 |
| 01 Apr 2026 | Dr. Gabriel Yamamoto Tier 1 Christie NHS Foundation Trust | ABDr. Anna Becker | Scientific exchange | In person | Nephrada | Treatment burden and fatigueAPRIL pathway mechanism+1 | 0 | — | Reviewed | Manual | ENG-0154 |
| 31 Mar 2026 | Dr. William Ivanova Tier 1 Gustave Roussy | JWJames Whitfield | Congress meeting | In person | Vantrexa | Chemotherapy-free first line | 1 | Compliance | Reviewed | Veeva CRM | ENG-0051 |
| 31 Mar 2026 | Dr. Mariana Rossi Tier 2 McGill University Health Centre | LOLuis Ortega | Scientific exchange | In person | Lumeva | Real-world persistenceMedication-overuse headache | 0 | MI request | Reviewed | Veeva CRM | ENG-0193 |
| 31 Mar 2026 | Dr. Javier Tanaka Tier 3 UCLH | RARachel Adeyemi | Advisory board | Virtual | Aurelin | Long-term safety monitoringPhase IIb efficacy+1 | 0 | — | Reviewed | Veeva CRM | ENG-0240 |
| 30 Mar 2026 | Dr. Tomoko Vogel Tier 1 Ospedale San Raffaele | RARachel Adeyemi | Payer / HTA meeting | Phone | Vantrexa | Duration of responseElderly / ECOG 2 patients+1 | 0 | — | Reviewed | Veeva CRM | ENG-0080 |
| 29 Mar 2026 | Dr. Noor Yamamoto Tier 1 Institut Curie | ABDr. Anna Becker | Scientific exchange | Phone | Nephrada | Treatment burden and fatiguePatient-reported outcomes | 0 | — | Reviewed | Veeva CRM | ENG-0141 |
| 24 Mar 2026 | Dr. Valentina Nakamura Tier 1 MD Anderson Cancer Center | ABDr. Anna Becker | Scientific exchange | Virtual | Nephrada | Steroid-sparing strategiesAPRIL pathway mechanism+1 | 0 | — | Reviewed | Veeva CRM | ENG-0122 |
| 24 Mar 2026 | Dr. Ulrich Tanaka Tier 3 Peter MacCallum Cancer Centre | LOLuis Ortega | Scientific exchange | In person | Lumeva | Drug interactionsSwitching between CGRP agents | 0 | — | Reviewed | Veeva CRM | ENG-0201 |
| 23 Mar 2026 | Prof. Benedikt Fischer Tier 1 Charité Berlin | RARachel Adeyemi | Advisory board | Phone | Vantrexa | PD-L1 testing turnaroundBrain-metastasis subgroup data+1 | 0 | — | Reviewed | Veeva CRM | ENG-0091 |
| 23 Mar 2026 | Dr. Javier Ivanova Tier 1 Johns Hopkins | JWJames Whitfield | Scientific exchange | Phone | Vantrexa | Brain-metastasis subgroup dataInfusion-reaction management | 0 | — | Reviewed | Veeva CRM | ENG-0109 |
| 22 Mar 2026 | Dr. Sven Nakamura Tier 1 National Cancer Center Tokyo | MTMei Tanaka | Payer / HTA meeting | In person | Vantrexa | Chemotherapy-free first line | 1 | — | Reviewed | Veeva CRM | ENG-0069 |
| 22 Mar 2026 | Dr. Farah Fischer Tier 2 MD Anderson Cancer Center | JWJames Whitfield | Scientific exchange | Virtual | Lumeva | Chronic migraine data | 0 | — | Reviewed | Veeva CRM | ENG-0186 |
| 21 Mar 2026 | Dr. Hiroshi Zimmermann Tier 1 Gustave Roussy | RARachel Adeyemi | Congress meeting | In person | Vantrexa | PD-L1 testing turnaround | 1 | — | Reviewed | Veeva CRM | ENG-0062 |
| 21 Mar 2026 | Dr. Zoë Meyer Tier 2 Christie NHS Foundation Trust | ABDr. Anna Becker | Congress meeting | Virtual | Nephrada | APRIL pathway mechanism | 0 | — | Reviewed | Veeva CRM | ENG-0140 |
| 19 Mar 2026 | Dr. Yuki Quinn Tier 2 Osaka University Hospital | RARachel Adeyemi | Scientific exchange | Virtual | Vantrexa | Brain-metastasis subgroup dataComparator checkpoint monotherapy+1 | 0 | — | Reviewed | Veeva CRM | ENG-0075 |
| 17 Mar 2026 | Dr. Gabriel Ueda Tier 1 Institut Curie | RARachel Adeyemi | Congress meeting | Phone | Vantrexa | PD-L1 testing turnaroundComparator checkpoint monotherapy+1 | 1 | MI request | Reviewed | Veeva CRM | ENG-0006 |
| 17 Mar 2026 | Dr. Ulrich Zimmermann Tier 2 Cleveland Clinic | MTMei Tanaka | Advisory board | In person | Vantrexa | Chemotherapy-free first linePD-L1 testing turnaround | 0 | — | Reviewed | Veeva CRM | ENG-0070 |
| 16 Mar 2026 | Dr. Liam Quinn Tier 3 Institut Curie | ABDr. Anna Becker | Scientific exchange | In person | Nephrada | eGFR slope interpretationPatient-reported outcomes | 0 | — | Reviewed | Veeva CRM | ENG-0161 |
| 13 Mar 2026 | Dr. Daniel Weber Tier 1 Royal Marsden | ABDr. Anna Becker | Congress meeting | Virtual | Nephrada | eGFR slope interpretation | 0 | — | Reviewed | Veeva CRM | ENG-0153 |
| 13 Mar 2026 | Dr. Ingrid Dubois Tier 3 Policlinico Gemelli | JWJames Whitfield | Scientific exchange | In person | Lumeva | Medication-overuse headache | 0 | — | Reviewed | Veeva CRM | ENG-0166 |
| 12 Mar 2026 | Dr. Chloé Dubois Tier 3 Vall d'Hebron | RARachel Adeyemi | Advisory board | In person | Vantrexa | Brain-metastasis subgroup dataChemotherapy-free first line+1 | 0 | — | Reviewed | Manual | ENG-0012 |
| 12 Mar 2026 | Dr. Hiroshi Weber Tier 2 Princess Margaret Cancer Centre | JWJames Whitfield | Advisory board | In person | Lumeva | Chronic migraine data | 0 | — | Reviewed | Veeva CRM | ENG-0184 |
| 11 Mar 2026 | Dr. Gabriel Kimura Tier 1 UCLH | RARachel Adeyemi | Congress meeting | Phone | Aurelin | Adolescent population | 0 | — | Reviewed | Manual | ENG-0232 |
| 08 Mar 2026 | Dr. Javier Kimura Tier 3 Gustave Roussy | ABDr. Anna Becker | Investigator meeting | Virtual | Nephrada | Proteinuria as surrogate endpointPatient-reported outcomes | 0 | — | Reviewed | Veeva CRM | ENG-0159 |
| 08 Mar 2026 | Dr. Valentina Xu Tier 3 Royal Marsden | LOLuis Ortega | Investigator meeting | In person | Lumeva | Dosing in hepatic impairmentChronic migraine data+1 | 0 | — | Reviewed | Manual | ENG-0224 |
| 07 Mar 2026 | Dr. Ulrich Abbott Tier 1 Hôpital Pitié-Salpêtrière | JWJames Whitfield | Scientific exchange | In person | Vantrexa | Elderly / ECOG 2 patientsComparator checkpoint monotherapy+1 | 0 | — | Reviewed | Veeva CRM | ENG-0082 |
| 06 Mar 2026 | Dr. Quentin Zimmermann Tier 2 Universitätsklinikum Heidelberg | RARachel Adeyemi | Investigator meeting | In person | Aurelin | Long-term safety monitoring | 0 | Compliance | Reviewed | Manual | ENG-0228 |
| 05 Mar 2026 | Dr. Gabriel Kimura Tier 1 UCLH | RARachel Adeyemi | Scientific exchange | In person | Aurelin | JAK1/TYK2 selectivityPhase IIb efficacy | 0 | — | Reviewed | Manual | ENG-0234 |
| 02 Mar 2026 | Dr. Hiroshi Yamamoto Tier 3 Kyoto University Hospital | LOLuis Ortega | Payer / HTA meeting | Phone | Lumeva | Chronic migraine data | 0 | MI request | Reviewed | Veeva CRM | ENG-0171 |
| 02 Mar 2026 | Dr. Liam Eriksen Tier 3 Peter MacCallum Cancer Centre | LOLuis Ortega | Advisory board | In person | Lumeva | Drug interactions | 0 | — | Reviewed | Manual | ENG-0174 |
| 01 Mar 2026 | Dr. Paola Castellano Tier 1 Vall d'Hebron | JWJames Whitfield | Medical education | In person | Vantrexa | Infusion-reaction managementSequencing after progression+1 | 1 | — | Reviewed | Veeva CRM | ENG-0032 |
| 28 Feb 2026 | Dr. Andrea Eriksen Tier 3 Mayo Clinic | ABDr. Anna Becker | Scientific exchange | Virtual | Nephrada | Steroid-sparing strategies | 1 | — | Reviewed | Veeva CRM | ENG-0143 |
| 28 Feb 2026 | Dr. Tomoko Quinn Tier 1 Hospital Sírio-Libanês | LOLuis Ortega | Medical education | In person | Lumeva | Switching between CGRP agents | 1 | — | Reviewed | Veeva CRM | ENG-0225 |
| 27 Feb 2026 | Dr. Yuki Quinn Tier 2 Osaka University Hospital | RARachel Adeyemi | Advisory board | In person | Vantrexa | Brain-metastasis subgroup data | 0 | — | Reviewed | Veeva CRM | ENG-0107 |
| 24 Feb 2026 | Dr. Benedikt Dubois Tier 2 LMU Klinikum München | RARachel Adeyemi | Scientific exchange | In person | Vantrexa | Duration of responseChemotherapy-free first line+1 | 0 | MI request | Reviewed | Veeva CRM | ENG-0042 |
| 23 Feb 2026 | Dr. Daniel Weber Tier 1 Johns Hopkins | JWJames Whitfield | Scientific exchange | Virtual | Vantrexa | Elderly / ECOG 2 patients | 0 | — | Reviewed | Manual | ENG-0079 |
| 19 Feb 2026 | Dr. Quentin Eriksen Tier 3 Policlinico Gemelli | LOLuis Ortega | Scientific exchange | In person | Lumeva | Switching between CGRP agentsReal-world persistence | 1 | — | Reviewed | Veeva CRM | ENG-0211 |
| 17 Feb 2026 | Dr. Rosa Garcia Tier 3 Kyoto University Hospital | JWJames Whitfield | Scientific exchange | In person | Lumeva | Dosing in hepatic impairmentChronic migraine data | 0 | — | Reviewed | Veeva CRM | ENG-0183 |
| 16 Feb 2026 | Dr. Paola Castellano Tier 1 Vall d'Hebron | JWJames Whitfield | Medical education | In person | Vantrexa | Duration of responseSequencing after progression | 0 | MI request | Reviewed | Manual | ENG-0094 |
| 15 Feb 2026 | Dr. Chloé Dubois Tier 3 Osaka University Hospital | JWJames Whitfield | Scientific exchange | Phone | Vantrexa | Duration of responseElderly / ECOG 2 patients+1 | 0 | — | Reviewed | Veeva CRM | ENG-0061 |
| 12 Feb 2026 | Dr. Noor Sato Tier 1 Royal Melbourne Hospital | LOLuis Ortega | Scientific exchange | Phone | Lumeva | Chronic migraine dataReal-world persistence | 0 | — | Reviewed | Veeva CRM | ENG-0200 |
| 12 Feb 2026 | Dr. Tomoko Quinn Tier 1 Hospital Sírio-Libanês | LOLuis Ortega | Advisory board | Phone | Lumeva | Dosing in hepatic impairmentReal-world persistence | 1 | — | Reviewed | Veeva CRM | ENG-0203 |
| 11 Feb 2026 | Dr. Rosa Bauer Tier 1 Hospital Clínic Barcelona | RARachel Adeyemi | Scientific exchange | Phone | Vantrexa | PD-L1 testing turnaroundSequencing after progression | 0 | — | Reviewed | Veeva CRM | ENG-0026 |
| 11 Feb 2026 | Dr. Noor Yamamoto Tier 1 Institut Curie | ABDr. Anna Becker | Scientific exchange | Phone | Nephrada | Treatment burden and fatigueAPRIL pathway mechanism+1 | 0 | — | Reviewed | Veeva CRM | ENG-0119 |
| 08 Feb 2026 | Dr. Chloé Kimura Tier 1 Hôpital Pitié-Salpêtrière | MTMei Tanaka | Payer / HTA meeting | Phone | Vantrexa | Chemotherapy-free first line | 1 | MI request | Reviewed | Veeva CRM | ENG-0058 |
| 07 Feb 2026 | Dr. Sven Fischer Tier 3 Hôpital Pitié-Salpêtrière | RARachel Adeyemi | Scientific exchange | Phone | Vantrexa | Elderly / ECOG 2 patients | 1 | — | Reviewed | Veeva CRM | ENG-0087 |
| 07 Feb 2026 | Dr. Javier Ueda Tier 2 Johns Hopkins | JWJames Whitfield | Investigator meeting | Virtual | Lumeva | Dosing in hepatic impairment | 0 | — | Reviewed | Veeva CRM | ENG-0199 |
| 05 Feb 2026 | Dr. Chloé Dubois Tier 3 Vall d'Hebron | RARachel Adeyemi | Payer / HTA meeting | In person | Vantrexa | Infusion-reaction managementDuration of response | 0 | — | Reviewed | Veeva CRM | ENG-0083 |
| 03 Feb 2026 | Dr. Oscar Zimmermann Tier 2 UCSF Medical Center | RARachel Adeyemi | Scientific exchange | In person | Vantrexa | PD-L1 testing turnaroundComparator checkpoint monotherapy+1 | 1 | — | Reviewed | Veeva CRM | ENG-0085 |
| 03 Feb 2026 | Dr. Ulrich Hayashi Tier 2 Christie NHS Foundation Trust | ABDr. Anna Becker | Congress meeting | Virtual | Nephrada | APRIL pathway mechanismTreatment burden and fatigue+1 | 0 | — | Reviewed | Veeva CRM | ENG-0133 |
| 03 Feb 2026 | Dr. Daniel Weber Tier 1 Royal Marsden | ABDr. Anna Becker | Advisory board | In person | Nephrada | Treatment burden and fatigue | 1 | — | Reviewed | Veeva CRM | ENG-0150 |
| 03 Feb 2026 | Dr. Emiko Quinn Tier 2 A.C. Camargo Cancer Center | LOLuis Ortega | Payer / HTA meeting | In person | Lumeva | Drug interactionsSwitching between CGRP agents+1 | 0 | — | Reviewed | Manual | ENG-0192 |
| 03 Feb 2026 | Dr. Liam Dubois Tier 1 Peter MacCallum Cancer Centre | LOLuis Ortega | Investigator meeting | Virtual | Lumeva | Chronic migraine dataDrug interactions | 0 | — | Reviewed | Veeva CRM | ENG-0195 |
| 02 Feb 2026 | Dr. Rosa Jensen Tier 3 Uniklinik Köln | ABDr. Anna Becker | Payer / HTA meeting | Virtual | Nephrada | eGFR slope interpretation | 0 | — | Reviewed | Veeva CRM | ENG-0131 |
| 01 Feb 2026 | Dr. Noor Sato Tier 1 Royal Melbourne Hospital | LOLuis Ortega | Scientific exchange | In person | Lumeva | Drug interactionsDosing in hepatic impairment | 1 | — | Reviewed | Veeva CRM | ENG-0208 |
| 31 Jan 2026 | Dr. Javier Kimura Tier 3 Gustave Roussy | ABDr. Anna Becker | Investigator meeting | Virtual | Nephrada | Steroid-sparing strategies | 1 | — | Reviewed | Manual | ENG-0151 |
| 30 Jan 2026 | Dr. Tomoko Vogel Tier 1 Ospedale San Raffaele | RARachel Adeyemi | Congress meeting | In person | Vantrexa | Chemotherapy-free first linePD-L1 testing turnaround+1 | 0 | — | Reviewed | Veeva CRM | ENG-0016 |
| 29 Jan 2026 | Dr. William Abbott Tier 3 Universitätsklinikum Heidelberg | RARachel Adeyemi | Scientific exchange | Phone | Vantrexa | Chemotherapy-free first line | 0 | — | Reviewed | Veeva CRM | ENG-0111 |
| 26 Jan 2026 | Dr. Yuki Quinn Tier 2 Osaka University Hospital | RARachel Adeyemi | Scientific exchange | Phone | Vantrexa | Brain-metastasis subgroup dataComparator checkpoint monotherapy | 1 | — | Reviewed | Veeva CRM | ENG-0028 |
| 25 Jan 2026 | Dr. Chloé Fischer Tier 3 Kyoto University Hospital | JWJames Whitfield | Scientific exchange | In person | Vantrexa | Chemotherapy-free first line | 0 | — | Reviewed | Veeva CRM | ENG-0060 |
| 25 Jan 2026 | Dr. Gabriel Kimura Tier 1 UCLH | RARachel Adeyemi | Scientific exchange | Virtual | Aurelin | Adolescent population | 1 | MI request | Reviewed | Manual | ENG-0229 |
| 23 Jan 2026 | Dr. Oscar Petit Tier 1 Ospedale San Raffaele | RARachel Adeyemi | Congress meeting | In person | Vantrexa | Chemotherapy-free first line | 1 | — | Reviewed | Veeva CRM | ENG-0025 |
| 23 Jan 2026 | Dr. Daniel Kimura Tier 2 UCLH | ABDr. Anna Becker | Advisory board | In person | Nephrada | Patient-reported outcomesAPRIL pathway mechanism | 1 | — | Reviewed | Veeva CRM | ENG-0130 |
| 23 Jan 2026 | Dr. Benedikt Dubois Tier 3 Memorial Sloan Kettering | LOLuis Ortega | Congress meeting | In person | Lumeva | Real-world persistence | 1 | — | Reviewed | Veeva CRM | ENG-0175 |
| 22 Jan 2026 | Dr. Daniel Petit Tier 1 Hôpital Pitié-Salpêtrière | RARachel Adeyemi | Payer / HTA meeting | In person | Vantrexa | Elderly / ECOG 2 patients | 0 | — | Reviewed | Veeva CRM | ENG-0040 |
| 21 Jan 2026 | Dr. Emiko Olsen Tier 2 IEO Milano | RARachel Adeyemi | Congress meeting | Phone | Vantrexa | Comparator checkpoint monotherapy | 0 | MI request | Reviewed | Veeva CRM | ENG-0019 |
| 21 Jan 2026 | Dr. Tomoko Vogel Tier 2 Policlinico Gemelli | JWJames Whitfield | Scientific exchange | In person | Vantrexa | Brain-metastasis subgroup data | 0 | — | Reviewed | Manual | ENG-0022 |
| 18 Jan 2026 | Dr. Hiroshi Abbott Tier 3 Royal Marsden | RARachel Adeyemi | Advisory board | In person | Vantrexa | PD-L1 testing turnaroundChemotherapy-free first line+1 | 0 | — | Reviewed | Veeva CRM | ENG-0037 |
| 18 Jan 2026 | Dr. Daniel Tanaka Tier 3 Policlinico Gemelli | JWJames Whitfield | Payer / HTA meeting | Virtual | Vantrexa | Comparator checkpoint monotherapy | 0 | — | Reviewed | Veeva CRM | ENG-0084 |
| 17 Jan 2026 | Dr. Emiko Tanaka Tier 1 Uniklinik Köln | JWJames Whitfield | Scientific exchange | In person | Vantrexa | PD-L1 testing turnaroundChemotherapy-free first line+1 | 1 | — | Reviewed | Manual | ENG-0010 |
| 17 Jan 2026 | Dr. William Vogel Tier 3 UCLH | JWJames Whitfield | Scientific exchange | In person | Vantrexa | PD-L1 testing turnaroundSequencing after progression+1 | 0 | — | Reviewed | Veeva CRM | ENG-0055 |
| 17 Jan 2026 | Dr. Andrea Ueda Tier 1 Kyoto University Hospital | LOLuis Ortega | Medical education | In person | Lumeva | Dosing in hepatic impairmentDrug interactions | 0 | — | Reviewed | Veeva CRM | ENG-0216 |
| 17 Jan 2026 | Dr. Gabriel Vogel Tier 1 Uniklinik Köln | RARachel Adeyemi | Advisory board | Virtual | Aurelin | Phase IIb efficacyAdolescent population+1 | 1 | — | Reviewed | Veeva CRM | ENG-0231 |
| 16 Jan 2026 | Dr. Chloé Rossi Tier 3 Universitätsklinikum Heidelberg | JWJames Whitfield | Payer / HTA meeting | Phone | Vantrexa | Sequencing after progression | 1 | — | Reviewed | Veeva CRM | ENG-0047 |
| 16 Jan 2026 | Dr. Emiko Olsen Tier 2 IEO Milano | RARachel Adeyemi | Scientific exchange | Virtual | Vantrexa | Comparator checkpoint monotherapyElderly / ECOG 2 patients | 1 | — | Reviewed | Veeva CRM | ENG-0049 |
| 14 Jan 2026 | Dr. Andrea Abbott Tier 1 Memorial Sloan Kettering | RARachel Adeyemi | Congress meeting | In person | Vantrexa | Sequencing after progression | 0 | — | Reviewed | Veeva CRM | ENG-0095 |
| 14 Jan 2026 | Dr. Liam Quinn Tier 3 Institut Curie | ABDr. Anna Becker | Scientific exchange | Phone | Nephrada | Patient-reported outcomesProteinuria as surrogate endpoint+1 | 0 | — | Reviewed | Veeva CRM | ENG-0144 |
| 14 Jan 2026 | Dr. Ulrich Tanaka Tier 3 Peter MacCallum Cancer Centre | LOLuis Ortega | Scientific exchange | In person | Lumeva | Real-world persistence | 0 | — | Reviewed | Veeva CRM | ENG-0220 |
| 13 Jan 2026 | Dr. Tomoko Xu Tier 1 Universitätsklinikum Heidelberg | LOLuis Ortega | Scientific exchange | In person | Lumeva | Drug interactions | 0 | MI request | Reviewed | Veeva CRM | ENG-0170 |
| 08 Jan 2026 | Dr. Benedikt Castellano Tier 1 National Cancer Center Tokyo | LOLuis Ortega | Congress meeting | Virtual | Lumeva | Dosing in hepatic impairmentChronic migraine data | 0 | — | Reviewed | Veeva CRM | ENG-0169 |
| 07 Jan 2026 | Dr. Noor Abbott Tier 2 Hospital Clínic Barcelona | RARachel Adeyemi | Scientific exchange | Phone | Vantrexa | Brain-metastasis subgroup data | 1 | — | Reviewed | Veeva CRM | ENG-0054 |
| 07 Jan 2026 | Dr. Hiroshi Petit Tier 1 MD Anderson Cancer Center | ABDr. Anna Becker | Congress meeting | Phone | Nephrada | Proteinuria as surrogate endpoint | 1 | — | Reviewed | Veeva CRM | ENG-0125 |
| 05 Jan 2026 | Dr. Farah Kimura Tier 3 Memorial Sloan Kettering | JWJames Whitfield | Advisory board | Phone | Vantrexa | Sequencing after progressionDuration of response+1 | 0 | — | Reviewed | Veeva CRM | ENG-0076 |
| 05 Jan 2026 | Dr. Quentin Ueda Tier 1 Guy's and St Thomas' | ABDr. Anna Becker | Payer / HTA meeting | In person | Nephrada | Patient-reported outcomesTreatment burden and fatigue+1 | 0 | — | Reviewed | Veeva CRM | ENG-0139 |
| 05 Jan 2026 | Dr. Benedikt Lopez Tier 2 Mayo Clinic | RARachel Adeyemi | Medical education | In person | Aurelin | Phase IIb efficacyLong-term safety monitoring | 0 | — | Reviewed | Veeva CRM | ENG-0236 |
| 04 Jan 2026 | Dr. Chloé Dubois Tier 3 Vall d'Hebron | RARachel Adeyemi | Scientific exchange | In person | Vantrexa | Sequencing after progression | 0 | — | Reviewed | Veeva CRM | ENG-0074 |
| 04 Jan 2026 | Dr. Andrea Fischer Tier 2 Osaka University Hospital | LOLuis Ortega | Medical education | Phone | Lumeva | Dosing in hepatic impairmentDrug interactions+1 | 0 | — | Reviewed | Veeva CRM | ENG-0173 |
Privacy
| Name | Role | Institution | Country | TA | Tier | Scientific interests | Last engaged | Engagements | Insights | Consent | Source | Data quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dr. Daniel Tanaka STK-0001 | Thoracic medical oncologist | Policlinico Gemelli | Italy | Oncology | Tier 3 | Elderly patientsPD-L1 biomarkers | 85 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Valentina Hayashi STK-0002 | Oncology pharmacist | Hospital Clínic Barcelona | Spain | Oncology | Tier 2 | irAE managementElderly patients+1 | 83 days ago | 2 | 2 | Recorded | Veeva CRM | Good |
Dr. Chloé Rossi STK-0003 | Pathologist | Universitätsklinikum Heidelberg | Germany | Oncology | Tier 3 | Elderly patientsBrain metastases | 242 days ago | 0 | 1 | Recorded | Veeva CRM | Good |
Dr. Liam Jensen STK-0004 | Thoracic medical oncologist | Mayo Clinic | United States | Oncology | Tier 2 | PD-L1 biomarkersImmunotherapy sequencing | Never | 0 | 0 | Recorded | Veeva CRM | Needs review |
Dr. Sven Abbott STK-0005 | Thoracic medical oncologist | Policlinico Gemelli | Italy | Oncology | Tier 2 | PD-L1 biomarkers | 102 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Sven Meyer STK-0006 | Radiation oncologist | Christie NHS Foundation Trust | United Kingdom | Oncology | Tier 2 | Elderly patientsBrain metastases+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Javier Weber STK-0007 | Pathologist | Osaka University Hospital | Japan | Oncology | Tier 3 | irAE management | 138 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Noor Dubois STK-0008 | Thoracic medical oncologist | Osaka University Hospital | Japan | Oncology | Tier 3 | PD-L1 biomarkersImmunotherapy sequencing+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Yuki Quinn STK-0009 | Thoracic medical oncologist | Osaka University Hospital | Japan | Oncology | Tier 2 | PD-L1 biomarkers | 53 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Chloé Dubois STK-0010 | Oncology pharmacist | UCLH | United Kingdom | Oncology | Tier 3 | Immunotherapy sequencing | yesterday | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Noor Nakamura STK-0011 | Pathologist | Hospital La Paz | Spain | Oncology | Tier 2 | Brain metastasesPD-L1 biomarkers | 3 days ago | 2 | 0 | Pending | Veeva CRM | Good |
Dr. Zoë Yamamoto STK-0012 | Thoracic medical oncologist | Policlinico Gemelli | Italy | Oncology | Tier 1 | Immunotherapy sequencing | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Ulrich Zimmermann STK-0013 | Radiation oncologist | Cleveland Clinic | United States | Oncology | Tier 2 | irAE managementElderly patients | 114 days ago | 2 | 0 | Recorded | Veeva CRM | Good |
Dr. Chloé Kimura STK-0014 | Thoracic medical oncologist | Hôpital Pitié-Salpêtrière | France | Oncology | Tier 1 | PD-L1 biomarkersElderly patients+1 | 119 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Emiko Vogel STK-0015 | Oncology pharmacist | Charité Berlin | Germany | Oncology | Tier 3 | Brain metastasesirAE management+1 | today | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. William Vogel STK-0016 | Pathologist | UCLH | United Kingdom | Oncology | Tier 3 | PD-L1 biomarkers | 241 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Tomoko Ueda STK-0017 | Pathologist | Osaka University Hospital | Japan | Oncology | Tier 2 | PD-L1 biomarkers | 2 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Hiroshi Zimmermann STK-0018 | Radiation oncologist | Gustave Roussy | France | Oncology | Tier 1 | Elderly patients | 178 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Chloé Fischer STK-0019 | Pathologist | Kyoto University Hospital | Japan | Oncology | Tier 3 | PD-L1 biomarkersBrain metastases | 233 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Valentina Yamamoto STK-0020 | Pathologist | Ospedale San Raffaele | Italy | Oncology | Tier 3 | irAE managementImmunotherapy sequencing+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Sven Fischer STK-0021 | Thoracic medical oncologist | Hôpital Pitié-Salpêtrière | France | Oncology | Tier 3 | PD-L1 biomarkers | 85 days ago | 3 | 2 | Recorded | Veeva CRM | Needs review |
Dr. Oscar Petit STK-0022 | Oncology pharmacist | Ospedale San Raffaele | Italy | Oncology | Tier 1 | Elderly patientsPD-L1 biomarkers | 17 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Tomoko Vogel STK-0023 | Radiation oncologist | Policlinico Gemelli | Italy | Oncology | Tier 2 | irAE managementElderly patients+1 | 237 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Rosa Bauer STK-0024 | Radiation oncologist | Hospital Clínic Barcelona | Spain | Oncology | Tier 1 | PD-L1 biomarkersElderly patients+1 | 216 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Gabriel Ueda STK-0025 | Radiation oncologist | National Cancer Center Tokyo | Japan | Oncology | Tier 2 | Brain metastasesElderly patients | 55 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Ximena Rossi STK-0026 | Radiation oncologist | Osaka University Hospital | Japan | Oncology | Tier 1 | irAE management | 13 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. William Ivanova STK-0027 | Radiation oncologist | Gustave Roussy | France | Oncology | Tier 1 | irAE management | 77 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Oscar Yamamoto STK-0028 | Oncology pharmacist | Memorial Sloan Kettering | United States | Oncology | Tier 3 | Elderly patientsBrain metastases | 114 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Zoë Eriksen STK-0029 | Thoracic medical oncologist | Memorial Sloan Kettering | United States | Oncology | Tier 1 | Brain metastasesPD-L1 biomarkers+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Andrea Castellano STK-0030 | Thoracic medical oncologist | Universitätsklinikum Heidelberg | Germany | Oncology | Tier 3 | Elderly patientsBrain metastases+1 | Never | 0 | 0 | Pending | Manual | Good |
Dr. Oscar Zimmermann STK-0031 | Thoracic medical oncologist | UCSF Medical Center | United States | Oncology | Tier 2 | Immunotherapy sequencingElderly patients+1 | 38 days ago | 2 | 3 | Recorded | Veeva CRM | Good |
Dr. Hiroshi Kimura STK-0032 | Radiation oncologist | LMU Klinikum München | Germany | Oncology | Tier 1 | Immunotherapy sequencing | Never | 0 | 0 | Pending | Veeva CRM | Needs review |
Dr. Hiroshi Hayashi STK-0033 | Thoracic medical oncologist | LMU Klinikum München | Germany | Oncology | Tier 1 | Brain metastases | 149 days ago | 1 | 0 | Recorded | Manual | Good |
Dr. Liam Quinn STK-0034 | Thoracic medical oncologist | Royal Marsden | United Kingdom | Oncology | Tier 1 | irAE management | 17 days ago | 5 | 2 | Recorded | Veeva CRM | Good |
Dr. Hiroshi Abbott STK-0035 | Radiation oncologist | Royal Marsden | United Kingdom | Oncology | Tier 3 | irAE management | 240 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Farah Kimura STK-0036 | Thoracic medical oncologist | Memorial Sloan Kettering | United States | Oncology | Tier 3 | PD-L1 biomarkers | 49 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Daniel Xu STK-0037 | Pathologist | Guy's and St Thomas' | United Kingdom | Oncology | Tier 3 | irAE managementBrain metastases | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. William Abbott STK-0038 | Radiation oncologist | Universitätsklinikum Heidelberg | Germany | Oncology | Tier 3 | Brain metastases | 119 days ago | 3 | 1 | Recorded | Veeva CRM | Good |
Dr. Emiko Olsen STK-0039 | Thoracic medical oncologist | IEO Milano | Italy | Oncology | Tier 2 | irAE management | 237 days ago | 0 | 1 | Recorded | Veeva CRM | Good |
Prof. Benedikt Fischer STK-0040 | Academic nephrologist | Charité Berlin | Germany | Nephrology | Tier 1 | Elderly patientsirAE management+1 | 4 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Noor Abbott STK-0041 | Oncology pharmacist | Hospital Clínic Barcelona | Spain | Oncology | Tier 2 | PD-L1 biomarkers | 54 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Mariana Rossi STK-0042 | Pathologist | Royal Marsden | United Kingdom | Oncology | Tier 3 | irAE management | 8 days ago | 2 | 0 | Recorded | Veeva CRM | Good |
Dr. Paola Bauer STK-0043 | Oncology pharmacist | Cleveland Clinic | United States | Oncology | Tier 3 | PD-L1 biomarkers | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Chloé Xu STK-0044 | Oncology pharmacist | Gustave Roussy | France | Oncology | Tier 2 | irAE managementBrain metastases | 9 days ago | 3 | 1 | Recorded | Veeva CRM | Good |
Dr. Ulrich Abbott STK-0045 | Pathologist | Hôpital Pitié-Salpêtrière | France | Oncology | Tier 1 | irAE managementElderly patients | 120 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Chloé Meyer STK-0046 | Pathologist | Kyoto University Hospital | Japan | Oncology | Tier 2 | Elderly patientsImmunotherapy sequencing+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Benedikt Ivanova STK-0047 | Oncology pharmacist | Osaka University Hospital | Japan | Oncology | Tier 2 | Brain metastases | 157 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Javier Ivanova STK-0048 | Radiation oncologist | Johns Hopkins | United States | Oncology | Tier 1 | irAE management | 36 days ago | 3 | 1 | Recorded | Veeva CRM | Good |
Dr. Hiroshi Castellano STK-0049 | Pathologist | Hôpital Pitié-Salpêtrière | France | Oncology | Tier 3 | Immunotherapy sequencingirAE management | Never | 0 | 0 | Recorded | Manual | Good |
Dr. Andrea Abbott STK-0050 | Thoracic medical oncologist | Memorial Sloan Kettering | United States | Oncology | Tier 1 | Brain metastasesImmunotherapy sequencing | 5 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Benedikt Fischer STK-0051 | Pathologist | Guy's and St Thomas' | United Kingdom | Oncology | Tier 2 | irAE management | 159 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Mariana Sato STK-0052 | Thoracic medical oncologist | Uniklinik Köln | Germany | Oncology | Tier 2 | PD-L1 biomarkersImmunotherapy sequencing+1 | 25 days ago | 3 | 1 | Recorded | Veeva CRM | Good |
Dr. Gabriel Ueda STK-0053 | Pathologist | Institut Curie | France | Oncology | Tier 1 | PD-L1 biomarkersImmunotherapy sequencing+1 | 47 days ago | 3 | 1 | Recorded | Manual | Good |
Dr. Emiko Quinn STK-0054 | Radiation oncologist | Kyoto University Hospital | Japan | Oncology | Tier 3 | Elderly patients | 29 days ago | 3 | 0 | Recorded | Veeva CRM | Needs review |
Dr. Daniel Petit STK-0055 | Pathologist | Hôpital Pitié-Salpêtrière | France | Oncology | Tier 1 | Immunotherapy sequencing | 236 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Chloé Dubois STK-0056 | Oncology pharmacist | Vall d'Hebron | Spain | Oncology | Tier 3 | PD-L1 biomarkers | 17 days ago | 2 | 0 | Recorded | Veeva CRM | Good |
Dr. Farah Jensen STK-0057 | Radiation oncologist | Kyoto University Hospital | Japan | Oncology | Tier 1 | Elderly patientsImmunotherapy sequencing | Never | 0 | 0 | Recorded | Manual | Good |
Dr. William Jensen STK-0058 | HTA assessor | NICE technical team | United Kingdom | Nephrology | Tier 2 | Surrogate endpointseGFR slope | 32 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Ulrich Kimura STK-0059 | Oncology pharmacist | Gustave Roussy | France | Oncology | Tier 1 | PD-L1 biomarkersBrain metastases+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Hiroshi Xu STK-0060 | Radiation oncologist | Hospital Clínic Barcelona | Spain | Oncology | Tier 2 | PD-L1 biomarkersirAE management | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Chloé Dubois STK-0061 | Pathologist | Osaka University Hospital | Japan | Oncology | Tier 3 | irAE managementBrain metastases | 212 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Daniel Weber STK-0062 | Thoracic medical oncologist | Johns Hopkins | United States | Oncology | Tier 1 | irAE management | 128 days ago | 2 | 2 | Recorded | Veeva CRM | Good |
Dr. Sven Nakamura STK-0063 | Oncology pharmacist | National Cancer Center Tokyo | Japan | Oncology | Tier 1 | PD-L1 biomarkersImmunotherapy sequencing | 177 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Oscar Xu STK-0064 | Oncology pharmacist | IEO Milano | Italy | Oncology | Tier 3 | Elderly patientsPD-L1 biomarkers | 100 days ago | 1 | 0 | Recorded | Veeva CRM | Needs review |
Dr. Benedikt Lopez STK-0065 | Pathologist | UCLH | United Kingdom | Oncology | Tier 3 | Elderly patients | 32 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Tomoko Vogel STK-0066 | Pathologist | Ospedale San Raffaele | Italy | Oncology | Tier 1 | Brain metastasesirAE management | 169 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Paola Castellano STK-0067 | Headache specialist | Vall d'Hebron | Spain | Neurology | Tier 1 | Medication-overuse headacheChronic migraine | 55 days ago | 1 | 2 | Recorded | Veeva CRM | Good |
Dr. Emiko Olsen STK-0068 | Oncology pharmacist | National Cancer Center Tokyo | Japan | Oncology | Tier 1 | Immunotherapy sequencing | Never | 0 | 0 | Recorded | Manual | Good |
Dr. Emiko Tanaka STK-0069 | Thoracic medical oncologist | Uniklinik Köln | Germany | Oncology | Tier 1 | Elderly patientsBrain metastases+1 | 127 days ago | 2 | 2 | Recorded | Veeva CRM | Good |
Dr. Benedikt Dubois STK-0070 | Thoracic medical oncologist | LMU Klinikum München | Germany | Oncology | Tier 2 | Immunotherapy sequencingBrain metastases | 52 days ago | 3 | 0 | Recorded | Veeva CRM | Good |
Dr. Farah Garcia STK-0071 | Pathologist | Hôpital Pitié-Salpêtrière | France | Oncology | Tier 3 | Elderly patients | 43 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Rosa Kimura STK-0072 | Oncology pharmacist | Christie NHS Foundation Trust | United Kingdom | Oncology | Tier 2 | PD-L1 biomarkersBrain metastases | 39 days ago | 2 | 0 | Recorded | Veeva CRM | Good |
Dr. Zoë Ivanova STK-0073 | Oncology pharmacist | Hospital La Paz | Spain | Oncology | Tier 1 | Elderly patients | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Ximena Eriksen STK-0074 | Thoracic medical oncologist | Vall d'Hebron | Spain | Oncology | Tier 3 | Immunotherapy sequencingBrain metastases | 31 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Yuki Castellano STK-0075 | Academic nephrologist | Gustave Roussy | France | Nephrology | Tier 3 | Patient-reported outcomesSurrogate endpoints+1 | 95 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Daniel Weber STK-0076 | Community nephrologist | Royal Marsden | United Kingdom | Nephrology | Tier 1 | eGFR slopeAPRIL pathway+1 | 152 days ago | 1 | 2 | Recorded | Veeva CRM | Good |
Dr. Daniel Vogel STK-0077 | Academic nephrologist | LMU Klinikum München | Germany | Nephrology | Tier 3 | APRIL pathwayPatient-reported outcomes+1 | 141 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Ulrich Hayashi STK-0078 | Renal pathologist | Christie NHS Foundation Trust | United Kingdom | Nephrology | Tier 2 | APRIL pathwaySurrogate endpoints+1 | 4 days ago | 3 | 1 | Recorded | Manual | Good |
Dr. Zoë Castellano STK-0079 | Renal pathologist | UCLH | United Kingdom | Nephrology | Tier 2 | Patient-reported outcomes | 136 days ago | 1 | 0 | Recorded | Veeva CRM | Needs review |
Dr. Zoë Meyer STK-0080 | Community nephrologist | Christie NHS Foundation Trust | United Kingdom | Nephrology | Tier 2 | APRIL pathwaySurrogate endpoints | 178 days ago | 1 | 0 | Recorded | Manual | Good |
Dr. Noor Yamamoto STK-0081 | Academic nephrologist | Institut Curie | France | Nephrology | Tier 1 | eGFR slopeSurrogate endpoints | 170 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Quentin Quinn STK-0082 | Academic nephrologist | Institut Curie | France | Nephrology | Tier 1 | Patient-reported outcomes | 132 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Javier Zimmermann STK-0083 | Community nephrologist | Christie NHS Foundation Trust | United Kingdom | Nephrology | Tier 2 | Patient-reported outcomes | 22 days ago | 2 | 0 | Recorded | Veeva CRM | Good |
Dr. Daniel Kimura STK-0084 | Academic nephrologist | UCLH | United Kingdom | Nephrology | Tier 2 | APRIL pathway | 235 days ago | 0 | 1 | Recorded | Veeva CRM | Needs review |
Dr. Quentin Ueda STK-0085 | Academic nephrologist | Guy's and St Thomas' | United Kingdom | Nephrology | Tier 1 | APRIL pathway | 94 days ago | 1 | 0 | Pending | Veeva CRM | Needs review |
Dr. Liam Quinn STK-0086 | Academic nephrologist | Institut Curie | France | Nephrology | Tier 3 | eGFR slopeSurrogate endpoints | 158 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Zoë Garcia STK-0087 | Academic nephrologist | Memorial Sloan Kettering | United States | Nephrology | Tier 1 | APRIL pathwayeGFR slope+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Zoë Jensen STK-0088 | Community nephrologist | Royal Marsden | United Kingdom | Nephrology | Tier 2 | Surrogate endpointsPatient-reported outcomes | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Rosa Jensen STK-0089 | Community nephrologist | Uniklinik Köln | Germany | Nephrology | Tier 3 | Patient-reported outcomesSurrogate endpoints | 79 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Quentin Jensen STK-0090 | Academic nephrologist | Hôpital Pitié-Salpêtrière | France | Nephrology | Tier 2 | Patient-reported outcomeseGFR slope+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Sven Eriksen STK-0091 | Academic nephrologist | Universitätsklinikum Heidelberg | Germany | Nephrology | Tier 2 | APRIL pathwayPatient-reported outcomes | 95 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Emiko Garcia STK-0092 | Academic nephrologist | Uniklinik Köln | Germany | Nephrology | Tier 3 | Patient-reported outcomes | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Yuki Meyer STK-0093 | Academic nephrologist | Guy's and St Thomas' | United Kingdom | Nephrology | Tier 1 | eGFR slopeAPRIL pathway+1 | 45 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Hiroshi Petit STK-0094 | Renal pathologist | MD Anderson Cancer Center | United States | Nephrology | Tier 1 | APRIL pathwaySurrogate endpoints | 154 days ago | 1 | 2 | Recorded | Veeva CRM | Good |
Dr. Paola Jensen STK-0095 | Community nephrologist | LMU Klinikum München | Germany | Nephrology | Tier 2 | Patient-reported outcomesSurrogate endpoints+1 | 156 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Benedikt Vogel STK-0096 | Community nephrologist | Universitätsklinikum Heidelberg | Germany | Nephrology | Tier 1 | Patient-reported outcomesAPRIL pathway+1 | 57 days ago | 3 | 1 | Recorded | Veeva CRM | Good |
Dr. Andrea Eriksen STK-0097 | Community nephrologist | Mayo Clinic | United States | Nephrology | Tier 3 | APRIL pathwaySurrogate endpoints+1 | 199 days ago | 0 | 1 | Recorded | Veeva CRM | Good |
Dr. Gabriel Rossi STK-0098 | Renal pathologist | Guy's and St Thomas' | United Kingdom | Nephrology | Tier 1 | eGFR slope | 8 days ago | 2 | 2 | Recorded | Manual | Good |
Dr. Benedikt Xu STK-0099 | Academic nephrologist | Universitätsklinikum Heidelberg | Germany | Nephrology | Tier 2 | Patient-reported outcomesSurrogate endpoints+1 | 46 days ago | 3 | 0 | Recorded | Veeva CRM | Needs review |
Dr. Rosa Rossi STK-0100 | Renal pathologist | Royal Marsden | United Kingdom | Nephrology | Tier 2 | APRIL pathwayPatient-reported outcomes | Never | 0 | 0 | Recorded | Veeva CRM | Needs review |
Dr. Tomoko Jensen STK-0101 | Renal pathologist | UCLH | United Kingdom | Nephrology | Tier 2 | eGFR slopePatient-reported outcomes+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Liam Jensen STK-0102 | Renal pathologist | Christie NHS Foundation Trust | United Kingdom | Nephrology | Tier 1 | Surrogate endpointseGFR slope+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Valentina Nakamura STK-0103 | Community nephrologist | MD Anderson Cancer Center | United States | Nephrology | Tier 1 | Surrogate endpoints | 175 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Gabriel Yamamoto STK-0104 | Academic nephrologist | Christie NHS Foundation Trust | United Kingdom | Nephrology | Tier 1 | Patient-reported outcomes | 59 days ago | 3 | 1 | Recorded | Veeva CRM | Good |
Dr. William Vogel STK-0105 | Community nephrologist | Uniklinik Köln | Germany | Nephrology | Tier 2 | Patient-reported outcomesAPRIL pathway | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Javier Kimura STK-0106 | Renal pathologist | Gustave Roussy | France | Nephrology | Tier 3 | Surrogate endpointseGFR slope | 106 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Mariana Rossi STK-0107 | Primary care physician | McGill University Health Centre | Canada | Neurology | Tier 2 | CGRP persistenceSwitching | 168 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Zoë Bauer STK-0108 | Primary care physician | McGill University Health Centre | Canada | Neurology | Tier 2 | SwitchingChronic migraine | 24 days ago | 3 | 2 | Recorded | Veeva CRM | Good |
Dr. Tomoko Quinn STK-0109 | Headache specialist | Hospital Sírio-Libanês | Brazil | Neurology | Tier 1 | Medication-overuse headacheCGRP persistence | 136 days ago | 1 | 3 | Recorded | Manual | Good |
Dr. Rosa Zimmermann STK-0110 | General neurologist | Peter MacCallum Cancer Centre | Australia | Neurology | Tier 2 | CGRP persistenceSwitching | 100 days ago | 1 | 0 | Recorded | Veeva CRM | Duplicate suspected |
Dr. Yuki Sato STK-0111 | Primary care physician | National Cancer Center Tokyo | Japan | Neurology | Tier 2 | CGRP persistenceMedication-overuse headache | Never | 0 | 0 | Recorded | Veeva CRM | Needs review |
Dr. Emiko Quinn STK-0112 | General neurologist | A.C. Camargo Cancer Center | Brazil | Neurology | Tier 2 | SwitchingChronic migraine+1 | 41 days ago | 1 | 0 | Pending | Veeva CRM | Good |
Dr. Farah Fischer STK-0113 | Primary care physician | MD Anderson Cancer Center | United States | Neurology | Tier 2 | Chronic migraineSwitching | 60 days ago | 2 | 0 | Recorded | Veeva CRM | Needs review |
Dr. Valentina Xu STK-0114 | Headache specialist | Royal Marsden | United Kingdom | Neurology | Tier 3 | CGRP persistenceSwitching+1 | 191 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Andrea Ueda STK-0115 | General neurologist | Kyoto University Hospital | Japan | Neurology | Tier 1 | CGRP persistence | 241 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Andrea Weber STK-0116 | General neurologist | McGill University Health Centre | Canada | Neurology | Tier 1 | SwitchingCGRP persistence | 124 days ago | 2 | 0 | Recorded | Veeva CRM | Good |
Dr. Liam Eriksen STK-0117 | Headache specialist | Peter MacCallum Cancer Centre | Australia | Neurology | Tier 3 | SwitchingCGRP persistence | 197 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Javier Bauer STK-0118 | Headache specialist | Ospedale San Raffaele | Italy | Neurology | Tier 2 | Switching | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Benedikt Rossi STK-0119 | Primary care physician | Hospital Clínic Barcelona | Spain | Neurology | Tier 3 | SwitchingMedication-overuse headache | 106 days ago | 2 | 1 | Pending | Veeva CRM | Needs review |
Dr. Oscar Ueda STK-0120 | General neurologist | Hospital Sírio-Libanês | Brazil | Neurology | Tier 2 | SwitchingMedication-overuse headache+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Farah Meyer STK-0121 | General neurologist | Kyoto University Hospital | Japan | Neurology | Tier 3 | Medication-overuse headacheChronic migraine | Never | 0 | 0 | Pending | Veeva CRM | Good |
Dr. Benedikt Castellano STK-0122 | Headache specialist | National Cancer Center Tokyo | Japan | Neurology | Tier 1 | CGRP persistenceChronic migraine+1 | 55 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Mariana Vogel STK-0123 | Primary care physician | Johns Hopkins | United States | Neurology | Tier 3 | SwitchingCGRP persistence | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Ximena Fischer STK-0124 | Primary care physician | Royal Marsden | United Kingdom | Neurology | Tier 1 | SwitchingMedication-overuse headache | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Farah Jensen STK-0125 | Primary care physician | Osaka University Hospital | Japan | Neurology | Tier 1 | SwitchingChronic migraine | Never | 0 | 0 | Recorded | Veeva CRM | Needs review |
Dr. Mariana Sato STK-0126 | General neurologist | IEO Milano | Italy | Neurology | Tier 1 | CGRP persistenceSwitching | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Hiroshi Weber STK-0127 | Primary care physician | Princess Margaret Cancer Centre | Canada | Neurology | Tier 2 | SwitchingMedication-overuse headache | 29 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Noor Sato STK-0128 | Primary care physician | Royal Melbourne Hospital | Australia | Neurology | Tier 1 | CGRP persistenceMedication-overuse headache | 67 days ago | 3 | 3 | Recorded | Veeva CRM | Good |
Dr. Quentin Abbott STK-0129 | General neurologist | Hospital Clínic Barcelona | Spain | Neurology | Tier 2 | Medication-overuse headacheChronic migraine+1 | 144 days ago | 1 | 0 | Recorded | Veeva CRM | Duplicate suspected |
Dr. Ingrid Dubois STK-0130 | General neurologist | Policlinico Gemelli | Italy | Neurology | Tier 3 | CGRP persistenceMedication-overuse headache | 186 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Ximena Jensen STK-0131 | Primary care physician | Hospital La Paz | Spain | Neurology | Tier 1 | SwitchingChronic migraine | 51 days ago | 2 | 2 | Recorded | Veeva CRM | Good |
Dr. Benedikt Dubois STK-0132 | Headache specialist | Memorial Sloan Kettering | United States | Neurology | Tier 3 | SwitchingCGRP persistence | 73 days ago | 2 | 2 | Recorded | Veeva CRM | Good |
Dr. Daniel Bauer STK-0133 | Primary care physician | Ospedale San Raffaele | Italy | Neurology | Tier 3 | Medication-overuse headacheCGRP persistence | Never | 0 | 0 | Recorded | Manual | Good |
Dr. Hiroshi Yamamoto STK-0134 | Primary care physician | Kyoto University Hospital | Japan | Neurology | Tier 3 | CGRP persistenceSwitching | 197 days ago | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Quentin Eriksen STK-0135 | Headache specialist | Policlinico Gemelli | Italy | Neurology | Tier 3 | SwitchingChronic migraine | 208 days ago | 0 | 1 | Recorded | Veeva CRM | Duplicate suspected |
Dr. Ximena Olsen STK-0136 | Primary care physician | IEO Milano | Italy | Neurology | Tier 2 | CGRP persistence | 127 days ago | 1 | 1 | Recorded | Manual | Good |
Dr. Zoë Vogel STK-0137 | General neurologist | IEO Milano | Italy | Neurology | Tier 2 | SwitchingMedication-overuse headache | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Mariana Lopez STK-0138 | Headache specialist | Hospital Sírio-Libanês | Brazil | Neurology | Tier 1 | CGRP persistenceChronic migraine | 122 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Chloé Ivanova STK-0139 | Headache specialist | Hospital Clínic Barcelona | Spain | Neurology | Tier 1 | SwitchingChronic migraine+1 | 150 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Ximena Bauer STK-0140 | General neurologist | Osaka University Hospital | Japan | Neurology | Tier 3 | Chronic migraineMedication-overuse headache+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Andrea Fischer STK-0141 | General neurologist | Osaka University Hospital | Japan | Neurology | Tier 2 | Chronic migraineMedication-overuse headache+1 | 143 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Ingrid Bauer STK-0142 | General neurologist | Hospital Clínic Barcelona | Spain | Neurology | Tier 1 | Chronic migraine | 7 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Ingrid Petit STK-0143 | Headache specialist | LMU Klinikum München | Germany | Neurology | Tier 3 | Chronic migraine | 80 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Javier Ueda STK-0144 | General neurologist | Johns Hopkins | United States | Neurology | Tier 2 | CGRP persistence | 220 days ago | 0 | 0 | Pending | Veeva CRM | Good |
Dr. Yuki Olsen STK-0145 | Headache specialist | Royal Melbourne Hospital | Australia | Neurology | Tier 1 | SwitchingMedication-overuse headache+1 | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Ulrich Tanaka STK-0146 | General neurologist | Peter MacCallum Cancer Centre | Australia | Neurology | Tier 3 | SwitchingChronic migraine+1 | 175 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Liam Dubois STK-0147 | Primary care physician | Peter MacCallum Cancer Centre | Australia | Neurology | Tier 1 | CGRP persistence | 103 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Tomoko Xu STK-0148 | Primary care physician | Universitätsklinikum Heidelberg | Germany | Neurology | Tier 1 | Medication-overuse headacheSwitching | 126 days ago | 1 | 0 | Recorded | Manual | Good |
Dr. Rosa Garcia STK-0149 | General neurologist | Kyoto University Hospital | Japan | Neurology | Tier 3 | Medication-overuse headacheChronic migraine+1 | 12 days ago | 3 | 0 | Recorded | Manual | Good |
Dr. Katarina Rossi STK-0150 | General neurologist | Charité Berlin | Germany | Neurology | Tier 3 | Medication-overuse headache | 28 days ago | 2 | 1 | Recorded | Veeva CRM | Good |
Dr. Gabriel Kimura STK-0151 | Dermatologist | UCLH | United Kingdom | Immunology | Tier 1 | JAK selectivity | 36 days ago | 1 | 1 | Recorded | Veeva CRM | Good |
Dr. Gabriel Vogel STK-0152 | Allergist | Uniklinik Köln | Germany | Immunology | Tier 1 | Long-term safetyJAK selectivity | 241 days ago | 0 | 1 | Recorded | Veeva CRM | Good |
Dr. Rosa Nakamura STK-0153 | Allergist | UCSF Medical Center | United States | Immunology | Tier 2 | Adolescent ADLong-term safety | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Andrea Ivanova STK-0154 | Allergist | Universitätsklinikum Heidelberg | Germany | Immunology | Tier 3 | JAK selectivity | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Quentin Zimmermann STK-0155 | Allergist | Universitätsklinikum Heidelberg | Germany | Immunology | Tier 2 | Adolescent ADLong-term safety+1 | 106 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Quentin Ueda STK-0156 | Allergist | LMU Klinikum München | Germany | Immunology | Tier 2 | Adolescent AD | 108 days ago | 1 | 0 | Recorded | Manual | Good |
Dr. Ximena Fischer STK-0157 | Dermatologist | LMU Klinikum München | Germany | Immunology | Tier 2 | Adolescent AD | 148 days ago | 1 | 0 | Recorded | Veeva CRM | Duplicate suspected |
Dr. Liam Olsen STK-0158 | Dermatologist | Uniklinik Köln | Germany | Immunology | Tier 2 | Long-term safetyJAK selectivity | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Andrea Olsen STK-0159 | Allergist | Johns Hopkins | United States | Immunology | Tier 2 | Long-term safetyAdolescent AD | Never | 0 | 0 | Recorded | Veeva CRM | Duplicate suspected |
Dr. Benedikt Lopez STK-0160 | Allergist | Mayo Clinic | United States | Immunology | Tier 2 | Long-term safety | 15 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Gabriel Tanaka STK-0161 | Allergist | LMU Klinikum München | Germany | Immunology | Tier 2 | Long-term safetyJAK selectivity | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Javier Tanaka STK-0162 | Dermatologist | UCLH | United Kingdom | Immunology | Tier 3 | Long-term safety | 168 days ago | 1 | 0 | Recorded | Veeva CRM | Good |
Dr. Ingrid Castellano STK-0163 | Dermatologist | MD Anderson Cancer Center | United States | Immunology | Tier 3 | JAK selectivityAdolescent AD | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Javier Petit STK-0164 | Dermatologist | MD Anderson Cancer Center | United States | Immunology | Tier 2 | JAK selectivityAdolescent AD | 162 days ago | 1 | 0 | Recorded | Manual | Good |
Dr. Sven Fischer STK-0165 | Allergist | Memorial Sloan Kettering | United States | Immunology | Tier 3 | Adolescent ADLong-term safety | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Noor Tanaka STK-0166 | Allergist | Cleveland Clinic | United States | Immunology | Tier 3 | Adolescent ADJAK selectivity | Never | 0 | 0 | Recorded | Veeva CRM | Good |
Dr. Rosa Eriksen STK-0167 | Dermatologist | Johns Hopkins | United States | Immunology | Tier 1 | Long-term safety | 148 days ago | 1 | 0 | Recorded | Veeva CRM | Duplicate suspected |
Dr. Noor Ueda STK-0168 | Allergist | UCSF Medical Center | United States | Immunology | Tier 2 | JAK selectivityAdolescent AD+1 | Never | 0 | 0 | Recorded | Manual | Good |
Share of stakeholders with at least one engagement in the last 6 months
| Tier | North America | Europe | Asia-Pacific | Latin America |
|---|---|---|---|---|
| Tier 1 | 78%(9) | 71%(35) | 50%(10) | 100%(2) |
| Tier 2 | 62%(13) | 61%(36) | 75%(8) | 50%(2) |
| Tier 3 | 33%(9) | 61%(33) | 36%(11) | —(0) |
Percent engaged; bracketed number is stakeholders in the cell. Green ≥ 75%, amber ≥ 50%, red below.
Assumption: planned contacts per year = Tier 1 × 4, Tier 2 × 2, Tier 3 × 1. Completed = submitted or reviewed engagements FY2026 to date.
| Tier | Stakeholders | Planned / yr | Completed YTD | % of plan |
|---|---|---|---|---|
| Tier 1 | 56 | 224 | 92 | 41% |
| Tier 2 | 59 | 118 | 77 | 65% |
| Tier 3 | 53 | 53 | 69 | 130% |
Year is 71% elapsed at 15 Sept 2026; a tier at or above 71% of plan is on schedule.
Tier 1 stakeholders never engaged or not engaged in the last 90 days, grouped by country
France 7
United States 6
Germany 5
Japan 5
United Kingdom 4
Spain 3
Italy 3
Australia 2
Brazil 2
Canada 1
Stakeholders with more than 6 engagements in the last 6 months
No stakeholder exceeds 6 engagements in 6 months.
Governance
n = 235 reviewed
1→5: 0 / 54 / 63 / 56 / 62
n = 235 reviewed
1→5: 0 / 63 / 56 / 59 / 57
n = 235 reviewed
1→5: 42 / 49 / 50 / 43 / 51
n = 235 reviewed
1→5: 44 / 49 / 47 / 55 / 40
Reviewed engagements with quality ratings
| Product | n | Scientific relevance | Strategic relevance | Depth of exchange | Actionability | Overall |
|---|---|---|---|---|---|---|
| Vantrexa | 111 | 3.6 | 3.4 | 2.9 | 3.0 | 3.2 |
| Nephrada | 48 | 3.4 | 3.6 | 3.3 | 3.0 | 3.3 |
| Lumeva | 62 | 3.5 | 3.5 | 3.0 | 3.0 | 3.3 |
| Aurelin | 14 | 3.5 | 3.6 | 3.4 | 2.8 | 3.3 |
Share of completed engagements
Frequency across completed engagements
| Content | Uses | Share |
|---|---|---|
| VOYAGE-1 pivotal data summary | 48 | |
| PD-L1 testing pathway infographic | 45 | |
| VTX core scientific deck v3.2 | 45 | |
| irAE management guide | 38 | |
| CGRP class review | 34 | |
| LMV persistence data summary | 31 | |
| Chronic migraine scientific platform | 31 | |
| NPH mechanism-of-action deck | 26 | |
| Surrogate-endpoint evidence review | 22 | |
| APRIL-IgAN Phase III topline | 22 | |
| JAK selectivity review | 10 | |
| ARL Phase IIb summary | 9 |